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Abstract:
Microarray analysis to simultaneously monitor expression activities in thousands of genes has
become a routine experiment in biomedical research during the past decade. The microar-
ray expression data generated by high throughput experiments may consist of thousands of
variables and therefore pose great challenges to researchers in a wide variety of statistical
and computational issues. A commonly encountered problem by researchers is to detect
genes differentially expressed between two or more conditions and is the major concern of
this thesis.
  In the first part of the thesis, we consider imputation of incomplete data in transcriptomic 
meta-analysis. In the past decade, a tremendous amount of expression profiles are generated 
and stored in the public domain and information integration by meta-analysis to detect dif- 
ferentially expressed (DE) genes has become popular to obtain increased statistical power 
and validated findings. Methods that combine p-values have been widely used in such a ge- 
nomic setting, among which the Fisher’s, Stouffer’s, minP and maxP methods are the most 
popular ones. In practice, raw data or p-values of DE evidence of the entire genome are often 
not available in a subset of genomic studies that are to be combined. Instead, only the de- 
tected DE gene lists under certain p-value threshold (e.g. DE genes with p-value< 0.001) are 
reported in journal publications. The truncated p-value information voided the aforemen- 
tioned meta-analysis methods and researchers are forced to apply less efficient vote counting
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method or na¨ıvely drop the studies with incomplete information. In the thesis, effective
imputation methods were derived for such situations with partially censored p-values. We
developed and compared three imputation methods – mean imputation, single random im-
putation and multiple imputation – for a general class of evidence aggregation methods of
which Fisher, Stouffer and logit methods are special examples. The null distribution of each
method was analytically derived and subsequent inference and genomic analysis frameworks
were established. Simulations were performed to investigate the type I error and power for
univariate case and the control of false discovery rate (FDR) for (correlated) gene expression
data. The proposed methods were also applied to several genomic applications in prostate
cancer, major depressive disorder (MDD), colorectal cancer and pain research.
  In the second part, we investigate statistical properties of adaptively weighted (AW) 
Fisher’s method. The traditional Fisher’s method assigns equal weights to each study, which 
are sim- ple in nature but can not always achieve high power for a variety of alternative 
hypothesis settings. Intuitively more weight should be assigned to the studies with higher 
power to detect the difference between different conditions. The AW-Fisher’s method, where 
the best binary 0/1 weights are determined by minimizing the p-value of the weighted test 
statistics, was proposed in Li and Tseng (2011). By using the order statistics technique, the 
searching space for adaptive weights reduces to linear complexity instead of exponential, 
which reduce the computational complexity dramatically, and a closed form is derived to 
compute the p-values for combining two studies, and an importance sampling algorithm is 
proposed to evaluate the p-values for combining more than two studies. Theoretical properties 
of the AW-Fisher’s method such as consistency and asymptotical Bahadur optimality (ABO) 
are also investigated. Simulations will be performed to verify the asymptotical Bahadur opti- 
mality of the AW-Fisher and compare the performance of AW-Fisher and Fisher’s methods.
  Meta-analysis of multiple genomic studies increases the statistical power of biomarker de- 
tection and therefore the work in this thesis could improve public health by providing more 
effective methodologies for biomarker detection in the integration of multiple genomic studies 
when the information is incomplete or when different hypothesis settings are tested.
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1.0 INTRODUCTION
The rapid development of high-throughput experimental technology in the past decade has
made the generation of genomic data increasingly affordable. This results in the rapid accu-
mulation of experimental data in the public domains. The Gene Expression Omnibus (GEO;
http://www.ncbi.nlm.nih.gov/geo/) is one example that is the largest public database to
store gene expression data.
Among the vast amounts of gene expression data stored in the public domain, it is common
that many of them were generated to test the same or similar hypothesis for the same dis-
ease. Since a single individual study in general only contains a limited number of samples,
the statistical power of the test is relatively low and the generalizability of the conclusions is
often unreliable. In order to improve the statistical power of the tests and provide validated
conclusions, it is very common in practice that researchers attempt to combine information
across different, independent studies. This is done using a class of meta-analysis methods
that are particularly useful in microarray data analysis.
In this thesis, I will emphasize on applying meta-analysis to microarray data. The Chapter 1
is outlined as follows. In section 1.1 I briefly review the microarray data analysis. In section
1.2, univariate meta-analysis methods and microarray meta-analysis are introduced. In
section 1.3 several complementary hypothesis settings are introduced, and several important
questions are posed that will be answered in this thesis and the structure of the dissertation
is outlined.
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1.1 MICROARRAY DATA ANALYSIS
In the past decades, microarray technology has become one of the most important and pow-
erful tools that many researchers use to monitor genome wide expression levels of genes.
In general a microarray may contain thousands of genes for a limited number of samples.
Commonly used statistical methods for microarray data analysis include class comparison,
multiple testing, class discovery, class prediction and pathway analysis and so on. Among
them, the most popular application is to compare the expression of a set of genes for different
conditions (for instance, cases versus controls).
Unlike the traditional epidemiological problems, microarrays monitor gene expression for
thousands of genes simultaneously. The standard data structure of a set of microarray data
are a series of rectangular matrices in which the rows represent the expression of genes and
the columns represent samples. Therefore, one can express the microarrays by ygsk, where
ygsk denotes the gene expression for the gth gene in the sth sample of the kth study for
g = 1, · · · , G; s = 1, · · · , S and k = 1, · · · , K. Usually samples are identified by a clinical
variable rsk indicating their classes. Thus, for a given study k, rsk ∈ {0, 1} represents a two-
class comparison problem and rsk ∈ {1, · · · , S} leads to a multi-class comparison problem.
Microarray meta-analysis usually refers to combining multiple transcriptomic studies for
detecting differentially expressed (DE) genes (or biomarkers) across two or more conditions
(e.g., case and control) with statistical significance and/or biological significance (e.g., fold
change). For DE gene detection, hypothesis testing (such as two-sample t-test) is performed
per gene. Since multiple hypothesis tests are performed, the problem of multiple comparisons
should be addressed. For example, N tests generate an average of αN significant genes or
biomakers at significance level α by chance. Therefore, false discovery rate (FDR) should
be controlled for microarray analysis. A widely used procedure to control FDR is the B-H
method proposed by [Benjamini and Hochberg, 1995].
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1.2 META-ANALYSIS AND MICROARRAY META-ANALYSIS
Meta-analysis refers to systematic methods that integrate information from different, in-
dependent studies by using statistical techniques. Although the name of ”meta-analysis”
was invented by Glass in 1976 [Glass 1976], some of the techniques of meta-analysis can be
traced back to a long time before that. Pearson performed the first meta-analysis in 1904 to
summarize the correlation coefficients across studies of typhoid vaccination (Pearson 1904).
Tippett (1931), Fisher (1948), and Wilkinson (1951) also proposed methods for to combine p-
values. Today, meta-analysis is widely used in epidemiology and the field of medical research.
In meta-analysis, two major types of statistical techniques have been used: combining effect
sizes and combining p-values.
1.2.1 Combining effect sizes
In the methods of combining effect sizes, the fixed effect model and random effect model are
most popular [Cooper et al., 2009]. These methods are usually more straightforward and
powerful to directly synthesize information of the effect size estimates and should be used in
priority when the effect sizes are well-defined and comparable across different studies.
1.2.1.1 Fixed effects model In fixed effect model, one assumes that there is one true
effect size θ and all the differences in observed effects are due to sampling error. In other
words, the fixed effect model can be written as
Tk = θ + k with k ∼ N(0, σ2k),
where Tk is the observed effect size of study k. So each effect size Tk estimates a single mean
effect θ, and differs from this mean effect by sampling error k.
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1.2.1.2 Random effects model In fixed effect models, the true effect size is assumed
to the same in all studies, which in many applications is implausible. More generally, in
random effect models, each effect size is assumed to differ from the underlying population
mean θ, due to both sampling error and the underlying population variance, i.e., the random
effect model can be writen as
Tk = θ + k + ζk with k ∼ N(0, σ2k), ζk ∼ N(0, τ 2).
1.2.2 Combining p-values
P-value combination methods are good alternatives of effect size combination methods when
the effect sizes are not directly comparable across different studies. The well-known p-value
combination methods include Fisher’s method [Fisher, 1948], Stouffer’s method [Stouffer,
1949], minP method [Tippett, 1931] and maxP method [Wilkinson, 1951].
These methods can be divided further into two classes: evidence aggregation methods and
order-statistics based methods. The maxP and minP methods are two commonly used order-
statistics based meta-analysis methods, since they use the order statistics of the observed
p-values as their test statistics. On the contrary, Fisher and Stouffer methods are among
the most popular evidence aggregation meta-analysis methods, in which the test statistics
are defined as the sum of selected transformations of p-values for each individual study, i.e,
the evidence is aggregated when new studies are included into the analysis. In this section,
we assume that the null hypothesis is H0 : ∩Kk=1{θk = 0}, where θk is the true effect size of
study k.
1.2.2.1 Evidence aggregation methods For evidence aggregation methods, given a
set of p-values {p1, · · · , pK}, the test statistic is defined as
T =
K∑
k=1
Tk :=
K∑
k=1
F−1X (pi),
where FX(·) is the cumulative distribution function (CDF) of some random variable X.
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In theory, any random variable X can be picked up to form a combining p-values method.
However, only those Xs such that the null distribution of T is simple under the null hypoth-
esis H0 are selected. In this thesis, we focus on three popular special cases:
1. Fisher’s method: When X ∼ χ22, Tk = F−1X (pk) = −2 log(pk).
2. Stouffer’s method: When X ∼ N(0, 1), Tk = F−1X (pk) = Φ−1(pk).
3. Logit method: When X ∼ Logistic(0, 1), Tk = − log pi1−pi and
√
3
pi2
5K+4
K(5K+2)
T ∼ t5K+4
approximately (Hedges and Olkin 1985) under null hypothesis. For K ≥ 5, it has been
further approximated
√
3
pi2
5K+4
K(5K+2)
T ∼ N(0, 1).
1.2.2.2 Order-statistic based methods Given a set of p-values {pk}Kk=1, let {p(k)}Kk=1
be its ordered version. Then for order-statistic based methods, the order statistic is selected
as the test statistic (Song and Tseng 2014), i.e.,
T := p(r) ∼ Beta(r,K − r + 1) for 1 ≤ r ≤ K.
Obviously minP and maxP are special cases with r = 1 and r = K respectively.
1.2.3 Microarray meta-analysis
When multiple microarray studies are available, meta-analysis can be used to increase the
statistical power for DE gene detection. Most meta-analytic methods for microarray studies
are based on extensions of the univariate meta-analysis methods used for traditional medical
research. Rhode was the first one to apply the conventional Fisher’s method for combining
multiple microarray studies [Rhode 2002]. In this thesis I will focus on the methods of com-
bining p-values. Since these test statistics have simple analytical forms of null distributions,
they are easy to apply to the genomic setting. Recall that given study k, suppose an appro-
priate test statistic Tk is selected for comparison {rsk, 1 ≤ s ≤ Sk} and the resulting p-values
for each gene g (denoted as pgk) can be derived from the observed expression intensities,
then for each fixed g, the conventional meta-analysis methods can be applied to {pgk}Kk=1 for
information integration. The final p-values obtained for each gene {pg}Gg=1 will be adjusted
by the B-H method to control the FDR, and the DE genes can be detected at different FDR
thresholds.
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1.3 COMPLEMENTARY HYPOTHESIS SETTINGS
In meta-analysis one needs to combine independent p-values from a set of hypothesis tests.
Given K individual hypotheses H0k : θk = 0 for k = 1, · · · , K, the joint null hypothesis is
defined as H0 : ∩Kk=1{θk = 0}. Obviously H0 is true only if all the effect sizes are 0 and
false when at least one effect size is non-zero. It has been shown that there is no uniformly
most powerful test, and some tests may be more powerful than others when some specific
alternative hypotheses are true.
Two commonly encountered hypothesis settings are defined at what follows:
HSA : H0 :
K⋂
k=1
{θk = 0} versus HA :
K⋂
k=1
{θk 6= 0},
HSB : H0 :
K⋂
k=1
{θk = 0} versus HA :
K⋃
k=1
{θk 6= 0}.
In order for the null hypothesis to be false, in HSA, the alternative hypothesis is the intersec-
tion event that effect sizes of all K studies are non-zero (i.e., the effect sizes in all studies are
zero), while HSB pursues non-zero effects in one or more studies (the alternative hypothesis
is the union event instead of intersection in HSA). Obviously, HSA is more stringent and
more desirable to identify consistency across all studies if the combined studies are homoge-
neous. HSB, however, is useful when heterogeneity in effect sizes is expected.
HSA and HSB are closely related to two often-asked biological questions in genomic studies:
”Which genes are significant in one or more data sets?” and ”Which genes are significant
in all data sets?”. It is easy to know that the maxP method targets on HSA and all other
combining p-value methods target on HSB.
Note that since in practice it is a priori unknown which individual null hypotheses are false,
it is difficult for researchers to select appropriate hypothesis test with high power. In or-
der to find a test which can achieve good power properties across such uncertainty, a new
complementary hypothesis setting HSr is defined as
HSr : H0 versus Hr :
r⋂
k=1
{θk 6= 0} and
K⋃
k=r+1
{θk = 0}.
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In order the null hypothesis is false, at least r effect sizes should be non-zero.
1.4 SCOPE OF THE THESIS
In this thesis, I will focus on methods of combining p-values, which in turn implies that in
order to utilize the methods, the p-value of each study is available in advance. Although
this is generally true in conventional meta-analysis, it is not unusual that in many genomic
studies the raw data are unavailable and only a partial DE gene list is reported with a given
p-value threshold [Griffth et. al., 2006]. Therefore, for some gene g, only the range of pgk is
available, i.e., whether the gene is differentially expressed at a given p-value threshold αk.
The na¨ıve methods which drop either the genes or the studies with incomplete information
are not plausible, because they neglect the rich information contained in the truncated data.
Therefore, there are practical needs to develop meta-analysis approaches that can efficiently
combine truncated p-value information. One solution is to impute the truncated p-values
before applying conventional meta-analysis. In this thesis, three imputation methods - the
mean imputation, the single random imputation and the multiple imputation - are applied.
In chapter 2, I investigate the imputation of truncated p-values for evidence aggregation
meta-analysis methods.
When integrating multiple genomic studies, the expression patterns of genes may vary in a
study specific manner. Li and Tseng proposed an adaptively weighted Fisher’s method (AW-
Fisher) to uncover the altered gene expression pattern across different studies [Li and Tseng,
2011], in which they started with the weighted statistic Ug(wg) = −
∑K
k=1wgk log(pgk), where
wgk ∈ {0, 1} is the weighted assigned to the kth study and wg = (wg1, · · · , wgK). Denoting
by pU(ug(wg)) the corresponding p-value, the adaptively weighted statistic is defined as the
minimal p-value among all possible weights:
V AWg = min
wg
pU(ug(wg)) and wˆg = arg min
wg
pU(ug(wg)).
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The resulting weight wˆg reflects a natural biological interpretation of whether or not a study
contributes to the statistical significance of a gene.
Recall that the number of studies where the null hypotheses are false is unknown a pri-
ori, the proposed AW-Fisher’s method can maintain good power properties across such an
uncertainty. In chapter 3, the AW-Fisher’s method is generalized to a class of evidence aggre-
gation meta-analysis methods and some properties such as the linear searching complexity,
the asymptotical consistency of the weights and the asymptotic Bahadur optimality of the
proposed tests will be investigated.
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2.0 IMPUTATION OF TRUNCATED P-VALUES FOR EVIDENCE
AGGREGATION META-ANALYSIS METHODS AND ITS GENOMIC
APPLICATION
2.1 INTRODUCTION AND MOTIVATION
Microarray analysis to monitor expression activities in thousands of genes simultaneously has
become routine in biomedical research during the past decade. The rapid development in bio-
logical high-throughput technology results in a tremendous amount of experimental data and
many datasets are available from public domains such as Gene Expression Omnibus (GEO)
and ArrayExpress. Since most microarray studies have relatively small sample sizes and
limited statistical power, integrating information from multiple transcriptomic studies using
meta-analysis techniques is becoming popular. Microarray meta-analysis usually refers to
combining multiple transcriptomic studies for detecting differentially expressed (DE) genes
(or candidate markers). DE gene analysis identifies genes differentially expressed across two
or more conditions (e.g., cases and controls) with statistical significance and/or biological
significance (e.g., fold change). Microarray meta-analysis in many situations refers to per-
forming traditional meta-analysis techniques on each gene repeatedly and then controlling
the false discovery rate (FDR) to adjust p-values for multiple comparison (Borovecki et al
2005; Cardoso et al. 2007; Pirooznia et al. 2007; Segal et al. 2004). Fisher’s method (Fisher
1931) was the first meta-analysis technique introduced in microarray data analysis in 2002
(Rhodes et al. 2002), followed by Tippett’s minimum p-value method in 2003 (Moreau et al.
2003). Subsequently many meta-analysis approaches have been used in this field, including
extensions of existing meta-analysis techniques and novel methods to encompass the chal-
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lenges presented in the genomic setting (Choi et al. 2003, Choi et al. 2007, Moerau et al.
2003, Owen 2009, Li and Tseng 2011, and see the review paper Tseng et. al. 2012).
To combine findings from multiple research studies, one needs to know either the effect size or
the p-value for each study. Since the differences in data structures and statistical hypotheses
across multiple studies may make the direct combination of effect sizes impossible or the re-
sult suspicious, combining p-values from multiple studies is often more appealing. One major
category of combining p-value methods are evidence aggregation methods, which utilize sum-
mation of certain transformations of p-values as their test statistics and evidence will aggre-
gate when new studies are included. Among evidence aggregation methods, Fisher’s method
is the most well-known, in which the test statistic is defined as T Fisher = −2∑Kk=1 log(pk),
where K is the number of independent studies to be combined and pk is the p-value of
individual study k, 1 ≤ k ≤ K. Under the null hypothesis of no effect size in all studies
and assuming that studies are independent and models for assessing p-values are correctly
specified, T Fisher follows a chi-square distribution with degrees of freedom 2K. Fisher’s
method has been popular due to its simplicity and some theoretical properties, including
admissibility under Gaussian assumption (Birnbaum 1954 & 1955) and asymptotically Ba-
hadur optimality (ABO) under equal non-zero effect sizes across studies (Littel and Folk,
1971). Some variations of Fisher’s methods were proposed by using unequal weights or a
trimmed version of Fisher’s test statistic (Olkin and Saner, 2001). Another widely used ev-
idence aggregation method is the Stouffer’s method, in which the test statistic is defined as
T Stouffer =
∑K
k=1 Φ
−1(pk) (Stouffer 1949), where Φ(·) is the inverse CDF of standard normal
distribution.
In order to combine p-values, all p-values across studies should be known. In genomic appli-
cations, however, raw data and thus p-values are often not available and usually only a list of
statistically significant DE genes (p-value less than a threshold) is provided in the publication
(Griffith et. al., 2006). Although many journals and funding agencies have encouraged or en-
forced data sharing policies, the situation has only improved moderately. Many researchers
are still concerned about data ownership, and researchers whose studies are sponsored by
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private funding are not obligated to share data in the public domain. For example, in Chan
et. al (2007), publications of 23 colorectal cancer versus normal gene expression profiling
studies were collected to perform meta-analysis to identify consistently reported candidate
disease-associated genes. However only one raw dataset is available from the Gene Expres-
sion Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/, GSE3294) and most other papers
only provided a list of DE genes (and their p-values) under a pre-specified p-value threshold.
A second motivating example comes from a microarray meta-analysis study for pain research
(LaCroix-Fralish 2011), in which 20 microarray studies of pain models were collected to de-
tect the gene signature and patterns of pain conditions. Among the 20 studies, only one raw
dataset was available on the author’s website and all the other papers reported the DE gene
lists under different thresholds.
In these two motivating examples (details to be shown in Section 4.1 and 4.2), the incom-
plete data forced researchers to either drop studies with incomplete p-values or apply the
convenient vote counting method (Hedges and Olkin, 1980). Dropping studies with incom-
plete information greatly reduces statistical power and is obviously not applicable in the two
motivating examples since only one study was available with complete data. The conven-
tional vote counting procedure is well-known as flawed and low-powered (McCarley et al.,
2001). Ioannidis et al., (2009) attempted to reproduce 18 microarray studies published in
Nature Genetics during 2005-2006. Interestingly, only two were ”in principle” replicated,
six ”partially” replicated and ten could not be reproduced. This result illustrates well the
wide-spread difficulty of obtaining raw data or reproducing published results in the field.
Therefore, developing methods to efficiently combine studies with truncated p-value infor-
mation is an important problem in microarray meta-analysis.
In this chapter, we assume that K = K1 + K2 studies are to be combined. In K1 studies,
the raw gene expression data matrix and sample annotations are available and the complete
p-values pgi (1 ≤ g ≤ G for genes and 1 ≤ i ≤ K1) can be reproduced for meta-analysis.
For the remaining K2 studies, either the raw data or annotation are not available. Only
incomplete information of a DE gene list (under p-value threshold αi for study i) is provided
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from the Journal publication. In this situation, the available information is an indicator
function 1{pgi≤αi} to represent whether the p-value of gene g in study i is smaller than αi
or not. We outline the chapter structure as the following. In Section 2.2, a general class
of evidence aggregation meta-analysis methods under univariate scenario are investigated
for the mean imputation, the single random imputation and the multiple imputation meth-
ods respectively, in which the exact or approximate null distributions are derived under the
null hypotheses and the results are shown for three popular special cases of Fisher, Stouffer
and Logit methods. Simulations for Fisher and Stouffer methods are performed in Section
2.3.1 to demonstrate the correct control of type I errors and the power of different im-
putation methods are compared with na¨ıve methods and complete cases in the univariate
meta-analysis scenario. In Section 2.3.2 simulations of expression profiles were performed to
compare performance of different methods. Simulations were further performed in Section
2.3.3 using 8 major depressive disorder (MDD) and 7 prostate cancer studies where raw
data were completely available and the true best performance (complete case) could be ob-
tained. In Section 2.4 the proposed methods were applied to the two motivating examples.
In Section 2.4.1 the proposed methods were applied to 7 colorectal cancer studies, where the
raw data are available only in 3 studies and the rest of 4 studies only have DE gene lists
under different p-value thresholds. In Section 2.4.2, the proposed methods were applied to
11 microarray studies of pain conditions, where no raw data was available.In Section 2.4.3,
we developed an unconventional application of the proposed methods to facilitate the large
computational and data storage needs in a liquid association meta-analysis. Discussions and
conclusions are included in Section 2.5.
12
2.2 METHODS AND INFERENCES
2.2.1 Evidence aggregation meta-analysis methods
Here we consider a general class of univariate evidence aggregation meta-analysis methods
(for gene g fixed), in which the test statistics are defined as the sum of selected transforma-
tions of p-values for each individual study. Without loss of generality, assuming that FX(·)
is the cumulative distribution function (CDF) of a random variable X, the test statistic T
is defined as
T =
K∑
i=1
Tk :=
K∑
k=1
F−1X (pk), (2.2.1)
where pk is the p-value of study k.
Theoretically X can be any continuous random variable. However, in practice, X is usu-
ally selected such that the test statistic T follows a simple distribution. For instance, when
X ∼ χ22, it holds T ∼ χ22K (Fisher’s method) and T ∼ N(0, K) holds, provided X ∼ N(0, 1)
(Souffer’s method).
The hypothesis that corresponds to testing the homogeneous effect sizes of K studies by
evidence aggregation methods is a union-intersection test (UIT) (Roy 1953):
H0 :
K⋂
k=1
{θk = 0} versus HA :
K⋃
k=1
{θk 6= 0}. (2.2.2)
In this paper, we focus on two popular special cases:
1. Fisher’s method (Fisher 1931): Tk = −2 log(pk), i.e., X ∼ χ22. Under null hypothesis,
T ∼ χ22K if studies are independent.
2. Stouffer’s method (Stouffer 1949): Tk = Φ
−1(pk), i.e., X ∼ N(0, 1). Under null hypothe-
sis, T ∼ N(0, K) if studies are independent.
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Another example is the logit method (Hedges and Olkin, 1985), where Tk = − log( pk1−pk ). But
since this method is rarely used in practice, we will not examine it further here. To apply
the evidence aggregation meta-analysis methods mentioned above, all the p-values should be
observed. However, in genomic applications, it often happens that p-values of some studies
are truncated and only their ranges are reported. Two na¨ıve methods are commonly used
to overcome this situation: vote counting method or the available-case method which only
combines studies with observed p-values. The available-case method discards rich informa-
tion contained in the studies with truncated p-values, and therefore the statistical power is
reduced. Hedges and Olkin (1980) showed that the power of vote counting converges to 0
when many studies of moderate effect sizes are combined and therefore the vote counting
method should be avoided whenever possible. In this section, three imputation methods -
mean imputation, single random imputation and multiple imputation method - are proposed
and investigated to combine studies with truncated p-values and the corresponding null dis-
tributions are derived analytically, respectively. We first define some notations.
Assume that K independent studies are to be combined and p1, · · · , pK are the correspond-
ing p-values. Without loss of generality, assume that all the p-values are available in the the
first K1 studies and only the indicator function of DE evidence are reported in the other K2
studies.
Define a pair (ci, xi), i = 1, · · · , K for each study, in which ci is the ”censoring” indicator
satisfying
ci :=
 0, if pi is observed( i.e., 1 ≤ i ≤ K1),1, if pi is censored( i.e., K1 + 1 ≤ i ≤ K), (2.2.3)
and xi is the final observed values which is defined as
xi :=
 pi, if ci = 0,
1{pi<αi}, if ci = 1,
(2.2.4)
where αi is the p-value threshold for study i (K1 + 1 ≤ i ≤ K1 + K2 = K). For each
i = 1, 2, · · · , K, one can impute the missing value by p˜i:
p˜i = pi · 1{ci=0} + [qi · 1{xi=1} + ri · 1{xi=0}] · 1{ci=1}
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with qi ∈ (0, αi), and ri ∈ [αi, 1). Section 2.2-2.4 develop three imputation methods for
selection of qi and ri.
2.2.2 Mean imputation method
The simplest imputation method is the mean imputation method, in which qi =
αi
2
and
ri =
1+αi
2
. Then the test statistic T˜ for truncated data satisfies
T˜ =
K∑
i=1
T˜i =
K∑
i=1
F−1X (p˜i) =
K1∑
i=1
F−1X (pi) +
K2∑
j=1
F−1X (p˜K1+j) = A+
K2∑
j=1
Bj, (2.2.5)
with A =
∑K1
i=1 F
−1
X (pi) and
Bj = F
−1
X (p˜K1+j) = F
−1(
αK1+j
2
) · 1{pK1+j<αK1+j} + F−1(
1 + αK1+j
2
) · 1{pK1+j≥αK1+j} (2.2.6)
for j = 1, · · · , K2. Recall that under null hypothesis, the random variable A satisfies
A ∼ χ22K1 for the Fisher’s method and A ∼ N(0, K1) for the Stouffer’s method. Obvi-
ously Bj follows a Bernoulli distribution.
The results can be summarized into the following theorem:
Theorem 2.2.1. For j = 1, 2, · · · , K2 and given t, by defining
bj = F
−1
X (
αK1+j
2
)− F−1X (
1 + αK1+j
2
) and c =
K2∑
j=1
F−1X (
1 + αK1+j
2
), (2.2.7)
it holds
P(T˜ ≤ t) =
∑
(j1,··· ,jK2 )∈{0,1}K2
ΠK2i=1α
ji
K1+i
(1− αK1+i)1−jiFA(t− c−
K2∑
i=1
jibi), (2.2.8)
where FA(·) is the CDF of A. Given the CDF, the expected values of test statistic T˜ under
null distributions can be calculated as follows.
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1. For the Fisher’s method, it holds
E(T˜ ) = 2K1 − 2
K2∑
j=1
[αK1+j log(
αK1+j
2
) + (1− αK1+j) log(
1 + αK1+j
2
)],
while the expectation of the original T is E(T ) = 2K1 + 2K2 = 2K.
2. For the Stouffer’s method, it holds
E(T˜ ) =
K2∑
j=1
[αK1+jΦ
−1(
αK1+j
2
) + (1− αK1+j)Φ−1(
1 + αK1+j
2
)],
while the expectation of the original T is E(T ) = 0.
Proof. Note that in this case, for j = K1 + 1, · · · , K, it holds
Bj = F
−1
X (
αj
2
) · 1{pi<αj} + F−1X (
1 + αj
2
) · 1{pi≥αj}. (2.2.9)
Let Yj ∼ Bernoulli(αj). Since pi ∼ Uniform(0, 1) under null hypothesis, it holds
Bj = [F
−1
X (
αj
2
)− F−1X (
1 + αj
2
)]Yj + F
−1
X (
1 + αj
2
) = bjYj + cj, (2.2.10)
and therefore
T˜ = A+
K2∑
j=1
bjYj + c with c =
K2∑
j=1
cj. (2.2.11)
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For given t, it holds
P(T˜ ≤ t) = P(A+
K2∑
i=1
biYi + c ≤ t) (2.2.12)
=
∑
(j1,··· ,jK2 )∈{0,1}K2
P(A+
K2∑
i=1
biYi + c ≤ t|Y1 = j1, · · · , YK2 = jK2)P(Y1 = j1, · · · , YK2 = jK2)
=
∑
(j1,··· ,jK2 )∈{0,1}K2
ΠK2i=1α
ji
i (1− αi)1−jiP(A ≤ t− c−
K2∑
i=1
jibi)
=
∑
(j1,··· ,jK2 )∈{0,1}K2
ΠK2i=1α
ji
i (1− αi)1−jiFA(t− c−
K2∑
i=1
jibi),
where FA(·) is the CDF of A.
Note that there are 2K2 terms summation in the right hand side of Equ. (2.8), which may
cause severe computing problem when K2 is large. However, when some αi are equal, the
formula can be simplified. Without loss of generality, assume there are r ≥ 1 different p-value
thresholds {β1, · · · , βr} such that
K2∑
j=1
1{αK1+j=β1} = n1, · · · ,
K2∑
j=1
1{αK1+j=βr} = nr and
r∑
l=1
nl = K2, (2.2.13)
then by defining f(j;nl, βl) := C
nl
j β
j
l (1 − βl)nl−j for j = 0, · · · , nl and l = 1, · · · , r, the
formula can be simplified as
P(T˜ ≤ t) =
n1∑
j1=0
· · ·
nr∑
jr=0
Πrl=1f(jl;nl, βl)FA(t− c−
r∑
l=1
jl(F
−1
X (
βl
2
)− F−1X (
1 + βl
2
))). (2.2.14)
Therefore, the summation is reduced from 2K2 terms to Πrl=1(nl + 1) terms.
From the above theorem one concludes that T˜ is a biased estimator of the original T . This
motivates the following two stochastic imputation methods.
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2.2.3 Single random imputation method
It is well-known that the mean imputation method will underestimate the variance of
{pK1+j}K2j=1 (Little and Rubin 2002). Furthermore, Theorem 2.2.1 shows that the test statis-
tic T˜ from the mean imputation method is a biased estimator of the original T . To avoid this
problem, one can replace the mean by randomly simulating qi and ri from Uniform(0, αi)
and Uniform(αi, 1) respectively.
Recall that for j = 1, · · · , K2, Bj = F−1X (p˜K1+j). The next theorem states that Bj ∼ X
holds under the null hypothesis, i.e., Bj and X follow the same distribution.
Theorem 2.2.2. For j = 1, 2, · · · , K2, it holds
Bj ∼ X. (2.2.15)
Proof. We show that for given t
P(Bi ≤ t) = P(F−1X (p˜i) ≤ t) = P(p˜i ≤ FX(t))
= P(xi = 1) ·P(p˜i ≤ FX(t)|xi = 1) +P(xi = 0) ·P(p˜i ≤ FX(t)|xi = 0)
= αiP[qi ≤ FX(t)] + (1− αi)P[ri ≤ Fx(t)]
=

αi · FX(t)αi = FX(t), if t ∈ (−∞, F−1X (αi)],
αi + (1− αi) · FX(t)−αi1−αi = FX(t), if t ∈ (F−1X (αi),∞)
= FX(t), (2.2.16)
which implies that
Bi ∼ X. (2.2.17)
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The following corollary is a simple consequence of the above theorem.
Corollary 2.2.3. For the single random imputation method, the following facts hold for T˜ :
1. For Fisher’s method, it holds Bj ∼ χ22 and T˜ ∼ χ22K.
2. For Stouffer method, it holds Bj ∼ N(0, 1) and T˜ ∼ N(0, K).
Therefore, in this case, T˜ is a unbiased estimator of T .
2.2.4 Multiple imputation method
Although the single random imputation method allows the use of standard complete-data
meta-analysis methods, it cannot reflect the sampling variability from one random sample.
The multiple imputation method (MI) overcomes this disadvantage (Little and Rubin 2002).
In MI, each missing value is imputed D times. Therefore {T˜ l}Dl=1 is a sequence of test
statistics which are defined as
T˜ l =
K∑
i=1
F−1X (p˜
l
i) = A+
K2∑
j=1
Blj, for l = 1, · · · , D (2.2.18)
with
qli ∼ Uniform(0, αi) and rli ∼ Uniform(αi, 1). (2.2.19)
The test statistic is defined as the average T = 1
D
∑D
l=1 T˜
l which satisfies,
T = A+
K2∑
j=1
[(
1
D
D∑
l=1
F−1X (q
l
K1+j
)) · 1{pK1+j<αK1+j} + (
1
D
D∑
l=1
F−1X (r
l
K1+j
)) · 1{pK1+j≥αK1+j}]
= A+
K2∑
j=1
[(
1
D
D∑
l=1
W lj) · 1{pK1+j<αK1+j} + (
1
D
D∑
l=1
V lj ) · 1{pK1+j≥αK1+j}]
= A+
K2∑
j=1
[W j · 1{pK1+j<αK1+j} + V j · (1− 1{pK1+j<αK1+j})] = A+
K2∑
j=1
Zj.
Since Zj = W j with probability αK1+j and Zj = V j with probability 1 − αK1+j, Zj is
a mixture distribution of W j and V j and therefore T − A is a mixture distribution of
{W j, V j, j = 1, · · · , K2}.
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Note that W lj and V
l
j are independent and identically distributed (i.i.d) for fixed j. Denote
by (µWj , σ
2
Wj
), (µVj , σ
2
Vj
) the mean and variance of W lj and V
l
j respectively. By the central
limit theorem one concludes that for large enough D > 0 it holds
W j = (
1
D
D∑
l=1
W lj) ∼ N(µWj ,
σ2Wj
D
), and V j = (
1
D
D∑
l=1
V lj ) ∼ N(µVj ,
σ2Vj
D
).
Then the following theorem holds.
Theorem 2.2.4. For (j1, · · · , jK2) ∈ {0, 1}K2, by defining U(j1, · · · , jK2) =
∑K2
i=1(jiW i +
(1− ji)V i) which satisfies
U(j1, · · · , jK2) ∼ N[
K2∑
i=1
(jiµWi + (1− ji)µVj),
1
D
K2∑
i=1
(jiσ
2
Wi
+ (1− ji)σ2Vj)], (2.2.20)
then for sufficiently large D, it holds approximately that
P(T ≤ t) =
∑
(j1,··· ,jK2 )∈{0,1}K2
ΠK2i=1α
ji
i (1− αi)1−jiP(A+ U(j1, · · · , jK2) ≤ t). (2.2.21)
The detailed notations are left to Section 2.2.5.
Similar to the mean imputation method, the formula can be simplified when some p-value
thresholds are equal, i.e.,
P(T ≤ t) =
n1∑
j1=0
· · ·
nr∑
jr=0
Πrl=1f(jl;nl, βl)P(A+ U(j1, · · · , jr) ≤ t), (2.2.22)
with U(j1, · · · , jr) =
∑r
l=1(jlF
−1
X (ql) + (nl − jl)F−1X (rl)), ql ∼ Uniform(0, βl) and rl ∼
Uniform(βl, 1).
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2.2.5 Some parameters in theorem 2.2.4 for the Stouffer’s and Fisher’s methods
2.2.5.1 Stouffer’s method It is easy to obtain that
µWi =
∫ α
0
1
α
· Φ−1(t)dt = 1
α
∫ Φ−1(α)
−∞
udΦ(u) = − 1
α
√
2pi
e−
[Φ−1(α)]2
2 , (2.2.23)
µVi =
∫ 1
α
1
1− α · Φ
−1(t)dt =
1
1− α
∫ ∞
Φ−1(α)
udΦ(u) =
1
(1− αi)
√
2pi
e−
[Φ−1(α)]2
2 .
and
σ2Wi = 1−
Φ−1(α)
α
√
2pi
e−
[Φ−1(α)]2
2 − 1
2piα2
e−[Φ
−1(α)]2 ,
σ2Vi = 1 +
Φ−1(α)
(1− α)√2pie
− [Φ−1(α)]2
2 − 1
2pi(1− α)2 e
−[Φ−1(α)]2 . (2.2.24)
2.2.5.2 Fisher’s method Similarly it holds
µWi =
∫ α
0
1
α
(−2 ln(t))dt = 2[1− lnα],
µVi =
∫ 1
α
1
1− α(−2 ln(t))dt = 2 +
2α
1− α ln(α), (2.2.25)
and
σ2Wi = E(W
2
i )− µ2Wi = 4,
σ2Vi = E(V
2
i )− µ2Vi = 4−
4α
(1− α)2 ln
2 α. (2.2.26)
2.3 SIMULATION RESULTS
Below we evaluate the proposed imputation methods using type I error and power in sim-
ulated data under univariate meta-analysis scenario in Section 2.3.1. In Section 2.3.2, we
extend to simulated microarray data with correlated gene structure and assess the perfor-
mance using the numbers of detected DE genes and false discovery rate (FDR). In Section
2.3.3, the proposed methods were applied to two real microarray datasets.
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2.3.1 Control of type I error and power analysis for univariate meta-analysis
In this subsection we perform simulations to study the type I errors and statistical power of
the proposed methods at various nominal levels of α. Two scenarios were used to investigate
the type I errors and powers respectively at what follows:
(I) Investigation on type I errors: two random samples {Xi}50i=1 and {Yi}50i=1 were both drawn
from N(0, 1);
(II) Investigation on powers: random samples {Xi}50i=1 ∼ N(0, 1) and {Yi}50i=1 ∼ N(0.3, 1).
T-test was used to compare the means of the two samples and the p-values were generated.
A vector of p-values with 8 entries, (p1, · · · , p8), was generated by repeating the process
eight times and among them 5 were selected for p-value truncation. The observed data
after truncation were (xi, ci) where xi = pi for ci = 0 (1 ≤ i ≤ 3) and xi = 1{pi<α} for
ci = 1 (4 ≤ i ≤ 8). The three proposed imputation methods (mean imputation, single
random imputation and multiple imputation) and available-case method were applied to the
truncated data and the corresponding p-values were calculated by the closed form solutions
forms given in Section 2.2. 1000 iterations were carried out and the proportion of cases that
gave significant difference in means between two samples was evaluated at a given nominal
level α = 0.05, 0.10 or 0.15, which gave the empirical estimation for the type I error and
powers respectively. For a full comparison, we also compared to the result using all eight
raw p-values without truncation. The simulations were repeated 20 times for scenario I and
scenario II to obtain the means and standard errors of the Type I errors and statistical power
respectively.
The error bar plots of the simulation results for Type I errors and statistical power are pre-
sented in Figure 2.1 and 2.2 respectively, where D is set to be 100 in multiple imputation
method. Figure 2.1 shows that all methods controlled their type I errors accurately for dif-
ferent significant level α. This is expected, because for all the methods we have derived their
exact (or good approximated) null distributions. Figure 2.2 shows that the three imputation
methods were more powerful than the available cases method, since they incorporated trun-
cated information neglected by the available-case method. Among the imputation methods,
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the single random imputation method has the lowest power. It took only one random draw
which could be a bad guess of the underlying true value. The mean imputation method
imputed by the mean value. Although it underestimated the variation in the imputation,
the bias seemed relatively small and it offered better power than the single random impu-
tation method. Multiple imputation method and mean imputation method achieved similar
statistical power at various significant level α. Comparing to the complete case situation,
we surprisingly found that mean imputation and multiple imputation methods could recover
most of the statistical power that the complete case situation could achieve (e.g., for α = 0.05
in Fisher’s method, power = 0.807 and 0.804 for mean and multiple imputation compared
to power = 0.887 for complete cases and power = 0.577 for available-case method.) This is
particularly notable since large amount of p-value information has been truncated (5 out of
8 studies) in this simulation.
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Figure 1: Type I error analysis. C: complete cases; A: available-case; Me: mean-imputation;
S: single-imputation; Mu: multiple imputation when α = 5%, 10% and 15%.
In order to investigate the performance of multiple imputation method across different impu-
tation number D, we repeated the two simulation scenarios for multiple imputation method
with D = {20, 40, 60, 80, 100, 120, 140, 160, 180} at significance level α = 0.05. Similarly the
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Figure 2: Power analysis. C: complete cases; A: available-case; Me: mean-imputation; S:
single-imputation; Mu: multiple imputation when α = 5%, 10% and 15%.
error bar plots of the simulation results for Type I errors and powers are presented in Figure
2.3 and 2.4 respectively. Figure 2.3 demonstrates that Type I error for both methods can be
well-controlled for moderately large D. In Figure 2.4 the horizontal dashed lines represent
the power obtained by setting D = 1000, where for Fisher’s method it is 0.805 and for Stouf-
fer’s method it is 0.797. Stouffer’s method appears to converge faster than Fisher’s method
probably because its truncated transformation of W lj and V
l
j is closer to a Gaussian distri-
bution. However, since the null distributions of the proposed multiple imputation method
were derived based on central limit theorem, we recommend to set D being at least 50 for
good approximation.
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Figure 3: Type I error analysis at α = 0.05 for different numbers of imputation D.
2.3.2 Simulated expression profiles
To evaluate performance of the proposed imputation methods in the genomic setting, we
simulated expression profiles with correlated gene structure and variable effect sizes as fol-
lows.
Step 1 Randomly sample gene cluster labels of 10, 000 genes (Cg ∈ {0, 1, 2, · · · , C} and 1 ≤
g ≤ G), such that C = 200 clusters each containing 20 genes are generated (∑g 1(Cg =
c) = 20, ∀1 ≤ c ≤ C = 200) and the remaining 6, 000 genes are unclustered genes
(
∑
g 1(Cg = 0) = 6, 000).
Step 2 For any cluster c (1 ≤ c ≤ C) in study k (1 ≤ k ≤ K), sample Σ′ck ∼ W−1(Ψ, 60), where
Ψ = 0.5I20×20 +0.5J20×20,W−1 denotes the inverse Wishart distribution, I is the identity
matrix and J is the matrix with all the entries being 1. Set vector σck as the square roots
of the diagonal elements in Σ′ck. Calculate Σck such that σckΣckσ
T
ck = Σ
′
gk.
Step 3 Denote by g
(c)
1 , · · · , g(c)20 as the indices for genes in cluster c. In other words, Cg(c)j =
c, where 1 ≤ c ≤ 200 and 1 ≤ j ≤ 20. Sample expression of clustered genes by
(X ′
g
(c)
1 nk
, · · · , X ′
g
(c)
20 nk
)T ∼ MVN(0,Σck), where 1 ≤ n ≤ N = 100 and 1 ≤ k ≤ K = 10.
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Sample expression for unclustered genes X ′gnk ∼ N(0, 1) for 1 ≤ n ≤ N and 1 ≤ k ≤ K
if Cg = 0.
Step 4 Sample effect sizes µgk from Unif(0.1, 0.5) for 1 ≤ g ≤ 1, 000 as DE genes and set µgk = 0
for 1, 001 ≤ g ≤ G as non-DE genes.
Step 5 For the first 50 control samples, Xgnk = X
′
gnk (1 ≤ g ≤ G, 1 ≤ n ≤ N/2 = 50, 1 ≤ k ≤
K). For cases, Ygnk = X
′
g(n+50)k + µgk (1 ≤ g ≤ G, 1 ≤ n ≤ N/2 = 50, 1 ≤ k ≤ K).
In the simulated datasets, K = 10 studies with G = 10, 000 genes were simulated. Within
each study, there were N
2
= 50 cases and 50 controls. The first 1, 000 genes were DE in all 10
studies with effect sizes randomly simulated from a uniform distribution on (0.1, 0.5) respec-
tively, and the remaining 9, 000 were non-DE genes. Therefore, the DE genes have different
effect sizes in different studies and the averaged mean effect size is (0.1 + 0.5)/2 = 0.3. In
each study, 200 gene clusters existed, each containing 20 genes. The correlation structure
within each cluster was simulated from an inverse Wishart distribution.
In the simulations, we performed a two sample t-test for each gene in each study and then
combined the p-values using the imputation methods proposed in this paper. For simplicity,
we viewed the p-values from the last 5 studies as truncated with thresholds (α1, · · · , α5) =
(0.001, 0.001, 0.01, 0.01, 0.05) respectively. In most genomic meta-analysis, researchers often
use conventional permutation analysis by permuting sample labels to compute the p-values
to preserve gene correlation structure. However, such a nonparametric approach is not
applicable in our situation, since raw data are not available in some studies. In order to
control the false discovery rate (FDR), we examined Benjamini-Hochberg (B-H) method
(Benjamini and Hochberg, 1995) and Benjamini-Yekutieli (B-Y) method (Benjamini and
Yekutieli, 2001) separately. The number of DE genes detected at nominal FDR rate 5%
were recorded and the true FDR rates were computed for each meta-analysis method by
FDR =
∑
g 1(gene g detected with g ≥ 1001)
#{genes detected} .
In the multiple imputation method, D = 50 was selected. Simulations were repeated for 50
times and the mean and standard errors of numbers of DE genes controlled by BH and BY
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methods and their true FDR are reported in Table 1. The results showed that the FDRs were
controlled well for B-H correction but rather conservative for B-Y correction (the true FDR
of B-Y is only 1/10 of B-H at nominal FDR = 5%). This is consistent with the previous ob-
servation that the B-Y adjustment tends to be over-conservative since it guards against any
type of correlation structure (Benjamini and Yekutieli, 2001). As a result, the BH correction
will be used for all applications hereafter. The simulation results showed consistently that
imputation methods had higher statistical power than the available-case method, and the
mean imputation and multiple imputation methods outperform single random imputation
method with similar performance. Surprisingly, the ratio of detected DE genes compared
to complete case increased from 41.6% in available case (263.5/632.9) to 80.4% in mean
imputation (508.6/632.9) using Fisher’s method. The improvement is even more significant
using Stouffer’s method (from 41.8% to 86.7%), while at the same time the true FDRs
were controlled at similar level for all methods. The result shows that imputation methods
successfully utilize the incomplete p-value information to greatly recover the detection power.
We further examined the situation when gene dependence structure does not exist (i.e. Steps
1-3 were skipped and X ′gnk ∼ N(0, 1) ). Table 2.2 shows the true Type I error control under
nominal significance level 5% (i.e.
True type I error =
∑10,000
g=1,001 1(gene g is detected at significance level 0.05)
9,000
). The result shows
adequate type I error control and confirms the validity of the closed form or approximated
formula of different imputation methods in Section 2.
To investigate the impact of D on the performance of multiple imputation method, simula-
tions were performed for D ∈ {20, 30, 50, 100, 150, 200, 250, 300, 500}. The result is shown in
Figure 2.4 which demonstrates that the performance of multiple imputation method is quite
robust for different number of imputation D. We use D = 50 throughout this thesis.
2.3.3 Simulation from complete real datasets
In this subsection, the proposed methods were applied to two real microarray datasets,
including 7 prostate cancer studies (Gorlov 2009) and 8 major depressive disorder (MDD)
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studies (Wang et al., 2012)). The details are summarized in Table 2.3. For each dataset,
about half of the studies (four for MDD and three for prostate cancer) were randomly selected
with p-value truncation threshold 0.05. Five methods including complete data, available-
case, single random imputation, mean imputation and multiple imputation methods were
applied to the datasets with the simulated incomplete data to impute by Stouffer’s and
Fisher’s methods respectively. The generated p-values were corrected by the B-H method
and the simulation was repeated for 50 times. Figure 1 shows boxplots of the numbers
of differentially expressed (DE) genes at FDR = 1% for different methods in MDD and
FDR = 0.5% for prostate cancer data. The result in Figure 2.6 indicates similar conclusion
that multiple imputation and mean imputation methods detect more DE genes than the
available-case method and single random imputation method. In the MDD example, very few
DE genes (average of 16 and 83 for Fisher and Stouffer respectively) were detected using the
available-case method if half of the studies have truncated p-values. The mean and multiple
imputation methods greatly improved the detection sensitivity. About 95.2% (Fisher) and
96.3% (Stouffer) of DE genes detected by the mean imputation method overlapped with
DE genes detected by complete data analysis in MDD and about 94.7% (Fisher) and 88.1%
(Stouffer) of DE genes detected by the mean imputation method overlapped with DE genes
detected by complete data analysis in prostate cancer, showing the ability of imputation
methods to recover DE gene detection power.
2.4 APPLICATIONS
2.4.1 Application to colorectal cancer
In the first motivating example, we followed Chan et. al. (2007) and attempted to collect 23
colorectal cancer versus normal gene expression profiling studies. Raw data were available in
only one study (Bianchini 2006) and other 4 studies containing more than 100 DE genes were
included in our analysis. We searched the GEO database and identified two additional new
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studies (Jiang et. al. 2008 and Bellot et. al. 2012). The seven studies under analysis were
summarized in Table 3. After gene-matching, 6, 361 genes overlapped in all three studies
with raw data. The available-case method, the mean imputation method, the single random
imputation method and the multiple imputation method were applied for the seven studies
for the Fisher and Stouffer methods respectively and the results were reported in Table 2.4.
For the single random imputation method and multiple imputation method, the analyses
were repeated 50 times and the mean and standard error of the number of DE genes detected
were reported under FDR control by the BH method. The results demonstrate that for
various FDR thresholds, the mean imputation method and the multiple imputation method
detected more DE genes than the available-case method and the single random imputation
method, which was consistent with previous findings in simulations. Under FDR = 0.01%
control, Fisher and Stouffer mean imputation detected 2.07 (1183/571) and 10.35 (383/37)
times of DE genes than those by available-case method, respectively.
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Table 1: Simulation results for correlated data matrix at nominal FDR=5%
Fisher Stouffer
Method/Mean(s.e.) No. DE True FDR No. DE True FDR
BH Complete cases 632.9(32.5) 0.043(0.0013) 518.6(36.2) 0.046(0.0015)
available-case 263.5(37.4) 0.048(0.0076) 216.8(35.3) 0.064(0.022)
Mean imputation 508.6(35.1) 0.046(0.0016) 449.8(36.2) 0.047(0.0022)
Single imputation 408.9(35.7) 0.043(0.0018) 293.9(32.6) 0.045(0.0027)
Multiple imputation 509.2(35.0) 0.045(0.0015) 463.8(35.7) 0.050(0.0019)
BY Complete cases 354.0(34.4) 0.0041(0.00083) 261.7(33.9) 0.0036(0.00097)
available-case 102.4(21.9) 0.0047(0.0012) 82.8(20.6) 0.0029(0.00096)
Mean imputation 234.5(32.1) 0.0037(0.00074) 203.8(30.8) 0.0034(0.00073)
Single imputation 164.0(27.3) 0.0057(0.0014) 113.5(22.3) 0.0039(0.0015)
Multiple imputation 235.3(32.0) 0.0037(0.00075) 216.1(30.9) 0.0050(0.0010)
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Table 2: Type I error control for independent data matrix at nominal significance level 5%
Fisher Stouffer
Complete cases 0.050(0.00031) 0.050(0.00037)
available-case 0.050(0.00035) 0.050(0.00033)
Mean imputation 0.050(0.00031) 0.050(0.00033)
Single imputation 0.050(0.00032) 0.051(0.00032)
Multiple imputation 0.050(0.00031) 0.051(0.00031)
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Figure 4: Number of DE genes at significance level 0.05 by multiple imputation method with
different numbers of imputation D. The dashed lines represent the theoretical asymptotic
power obtained by setting D = 1000.
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Table 3: Detailed data sets description
Author Year Platform Sample Size Source
(Case/Controls)
Welsh 2001 HG-U95A 34(25/9) public.gnf.org/cancer/
Prostate Cancer Singh 2002 HG-U95Av2 102(52/50) www.broad.mit.edu
Studies Lapointe 2004 cDNA 103(62/41) GSE3933
(Normal v.s Yu 2004 HG-U95Av2 83(65/18) GSE6919
Primary) Varambally 2005 HG-U133 Plus 2 13(7/6) GSE3325
(6940 genes) Wallace 2008 HG-U133A2 89(69/20) GSE6956
Nanni 2006 HG-U133A 30(23/7) GSE3868
MD1 AMY 2009 HG-U133 Plus 2 28(14/14) Dr. Sibille
MD1 ACC 2009 HG-U133 Plus 2 32(16/16) Dr. Sibille
MD3 ACC 2009 HumanHT-12 44(22/22) Dr. Sibille
MDD Studies MD2 ACC M 2010 HG-U133 Plus 2 18(9/9) Dr. Sibille
MD2 ACC F 2010 HG-U133 Plus 2 26(13/13) Dr. Sibille
(7570 genes) MD2 DLPFC M 2010 HG-U133 Plus 2 28(14/14) Dr. Sibille
MD2 DLPFC F 2010 HG-U133 Plus 2 32(16/16) Dr. Sibille
MD3 AMY 2009 HumanHT-12 42(21/21) Dr. Sibille33
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Figure 5: Number of DE genes detected by Fisher’s or Stouffer’s method. C: complete data;
A: available-case; Me: mean-imputation; S: single-imputation; Mu: multiple imputation
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Table 4: Seven colorectal cancer versus normal tissue expression profiling studies included in analysis
Study No. of samples No. of genes Raw data No. of DE No. of overlapped p-value
availability genes DE genes threshold
Bianchini 2006 24 7403 GSE3294 - - -
Bellot 2012 17 18191 GSE24993 - - -
Jiang 2008 48 18197 GSE10950 - - -
Grade 2007 103 21543 - 1950 635 1e-7
Croner 2005 33 22283 - 130 47 0.006
Kim 2004 32 18861 - 448 143 0.001
Bertucci 2004 50 8074 - 245 97 0.009
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Table 5: Summary of results for colorectal cancer
Fisher Stouffer
FDR Available Mean Single Multiple Available Mean Single Multiple
1% 2587 2855 2172.4(2.90) 2785.4(2.93) 1318 1675 668.4(3.96) 1616.0(2.10)
0.1% 1472 1874 1265.6(2.34) 1805.7(1.50) 299 709 252.7(1.93) 680.5(1.12)
0.01% 571 1183 748.4(1.89) 1138.6(2.00) 37 383 102.5(1.65) 366.7(0.69)
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2.4.2 Application to pain research
The second motivating example comes from the meta-analysis of 20 microarray studies of
pain to detect the patterns of pain (LaCroix-Fralish, 2011). The original meta-analysis uti-
lized DE gene lists from each study under different threshold criteria from p-value, FDR
or fold change and identified 79 ”statistically significant” genes that appeared in the DE
gene lists of four or more studies. The vote counting method essentially lost tremendous
amount of information with flawed statistical inference. When we attempted to repeat the
meta-analysis, raw data of only one of the 20 studies (Barr 2005) could be found. The old
platform used in that study, however, contained only 792 genes and had to be excluded from
further meta-analysis. In the remaining 19 studies, 11 studies contained DE gene lists under
various p-value thresholds (marked bold in Table 2.6) and were included in our application.
In other words, this example contained exclusively only studies with truncated p-values. Ta-
ble 2.7 shows the result of three imputation methods. Fisher and Stouffer identified 280 and
45 genes under 5% FDR control, respectively. Note that the original meta-analysis tested
the 79 genes using an overall binomial test and the statistical significance was controlled at
an overall p-value level, not at a gene-specific FDR level. As a result, DE gene lists from the
new imputation methods are theoretically more powerful and accurate.
To validate the finding, we used the Gene Functional Annotation tool from the DAVID
Bioinformatics Resources website (http://david.abcc.ncifcrf.gov). DAVID applied a modi-
fied Fisher’s exact test to evaluate the association between the DE gene lists and pathways.
Functional annotation of the 280 DE genes from the Fisher’s mean imputation method iden-
tified 208 pathways at FDR= 5%, among which selected important pain-related pathways
were grouped into five major biological categories and displayed in Table 6. In contrast,
the 79 genes from vote counting identified only 14 pathways, of which the expected pain-
related pathways under the categories of inflammation and of differentiation, development
and projection are missing (see Table 2.8). The pathway enrichment q-values after multiple
comparison control of the ”280 gene list” were very significant, while those of the ”79 gene
list” were not. Since the p-value calculation from Fisher’s exact test can be impacted by the
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DE gene size, we further compared the enrichment odd-ratios of genes in the pathway versus
in the DE gene list. Still the enrichment odds-ratios of the ”280 gene list” were generally
much higher than those for the ”79 gene list”, showing stronger pain functional association
from the Fisher’s mean imputation method.
2.4.3 Application to a three-way association method (liquid association)
In the literature, it has long been argued that positively correlated expression profiles are
likely to encode functionally related proteins. Liquid association (LA) analysis (Li 2002) is
an advanced three-way co-expression analysis beyond the traditional pairwise correlations.
For any triplet of genes X, Y and Z, the LA score LA(X, Y |Z) measures the effect that
expression of Z to control on and off of the co-expression between X and Y . For example,
high expression of Z turns on positive correlation between X and Y while when expression
of Z is low, X and Y are negatively or non-correlated. The theory in Li (2002) simplified
the calculation of the LA score to a linear order of sample size and made the genome-wide
computation barely feasible. Suppose we want to combine K studies of the liquid associa-
tion, liquid association p-values of all triplets in all K = 10 studies have to be stored for
meta-analysis. When the number of genes G = 1, 000, the number of p-values to be stored
is G · CG−12 ·K = 4.99GB. For a reasonable G = 20, 000 genome-wide analysis, storage size
for all p-values quickly increases to 39.99TB. One may argue that univariate (i.e. triplet
by triplet) meta-analysis may be applied repeatedly to avoid the need of storing all p-value
results. There are many other genomic meta-analysis situations when this may not be feasi-
ble. For example, in GWAS meta-analysis under a consortium collaboration, raw genotyping
data cannot be shared for privacy reasons and only the derived statistics or p-values can be
transferred for meta-analysis. Below we describe how imputation methods can help circum-
vent the tremendous data storage problem.
We performed a small scale of analysis on 566 DE genes previously reported from the meta-
analysis of the eight MDD studies used in Section 3.2 (Wang et al., 2012). The total number
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of possible triplets (X, Y |Z) was 90, 180, 780. By setting up p-value threshold at 0.001, we
only needed to store exact p-values for 2, 094, 123 (∼ 2.32%) triplets and the remaining
were truncated as considered in this paper. Since we also needed to store the truncation
index information, we only needed to store 2 × 2.32% = 4.64% of the information and the
compression ratio was 95.36%. To investigate the loss of information by the truncation,
Figure 2.7 indicates meta-analysis p-values (at − log(p) scale) from Fisher’s method using
full data and Fisher mean imputation method using truncated data. The result shows high
concordance in the top significant triplets, which are the major targets of this exploratory
analysis. Among the top 1000 triplets detected by Fisher’s method using complete p-value
information, 83.7% of them were also identified by the top 1000 by Fisher mean imputation.
The remaining 163 triplets were still in top ranks (rank between 1199 and 4763) using
truncated data in the result of Fisher mean imputation. This result suggests good potential
of applying data truncation to preserve the most informative information and performing
imputation to approximate the finding of the top targets when meta-analysis of ”big data” is
needed. The compression ratio may further increase by a more stringent truncation threshold
but the performance may somewhat decline as a trade-off.
2.5 DISCUSSION AND CONCLUSION
When combining multiple genomic studies by p-value combination methods, the raw data
are often not available and only the ranges of p-values are reported for some studies in
genomic applications. This is especially true for microarray meta-analysis since owners of
many microarray studies tend not to publish their data in the public domain. This incom-
plete data issue is often encountered when one attempts to perform a large-scale microarray
meta-analysis. If raw data are not available, two na¨ıve methods - vote counting method and
available-case method - are commonly used. Since these two methods completely or largely
neglect the information contained in the truncated p-values, and their statistical power is
generally low. In this chapter, we proposed three imputation methods for a general class of
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evidence aggregation meta-analysis methods to combine independent studies with truncated
p-values: mean imputation, single random imputation and multiple imputation methods.
For each proposed imputation method, the null distribution was derived analytically for the
Fisher and Stouffer methods. Theoretical results showed that the test statistics from the sin-
gle random imputation and the multiple imputation methods were unbiased, while those for
mean imputation method were biased. Simulations were performed for the imputed Fisher
method and imputed Stouffer method. The simulation results showed that type I errors
were well-controlled for all methods, which was consistent with our theoretical derivation.
Compared to the naive available-case method, all the imputation methods achieved higher
statistical powers, and the mean imputation and the multiple imputation methods recovered
much of the power that the complete cases method achieved even when half of the studies
had truncated p-values. Furthermore, Supplementary Figure 1 showed that the power of the
multiple imputation method was robust to the number of imputation D. Although small
to moderate D provided good results, we recommend choosing D being larger than 50 to
guarantee that central limit theorem can approximate well. Applications to two motivating
examples in colorectal cancer and pain conditions showed that both mean imputation and
multiple imputation performed among the best in terms of detection sensitivity and biolog-
ical validation by pathway analysis.
In regression-type missing-data imputation methods, the null distribution of the error term
is unknown and is assumed to be normally distributed with equal variance, a setting in which
multiple imputation method usually outperforms mean imputation in practice and in theory
(Little and Rubin 2002), particularly because mean imputation underestimates the true vari-
ance. However, our simulation results demonstrated that the power of the two methods were
quite similar. Two reasons may contribute to this result. First, although the test statistic
from the mean imputation method is biased and neglects the variation of truncated p-values,
its p-value can be computed accurately when the null distribution is derived analytically.
Second and more importantly, we find that the test statistic of mean imputation is in fact
F−1X (E(p)), while for sufficiently large D, the test statistic of multiple imputation converges
to E(F−1X (p)) in distribution. It is easy to show that these two quantities are very close
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to each other for a small range of p, provided F−1X (·) is smooth. Since F−1X (·) is infinitely
differentiable for the Fisher and Stouffer methods, and the small p-value range in (0, α) are
particularly of interest to us, it is not surprising that the mean imputation method and
multiple imputation method perform similarly. Since the mean imputation method achieved
almost the same power as the multiple imputation method with less computational com-
plexity, it is more appealing and is recommended for microarray meta-analysis, where the
imputed meta-analysis method is performed repeatedly for thousands of genes. In this paper
only the evidence aggregation meta-analysis methods are investigated and further work will
be needed to extended these results to order statistic based methods such as minP and maxP.
Note that although the truncated p-value issue discussed in this chapter may appear similar
to the problem of ”publication bias”, it is fundamentally different. Publication bias refers
to the fact that a study with a large positive treatment effect is more likely to be published
than a study with a relatively small treatment effect, resulting in bias if one only considers
published studies. Denote by p1, p2, · · · , pN the p-values of all conducted studies that should
have been collected. Only a subset of likely more significant p-values p1, p2, · · · , pn are ob-
served. Under this setting, N is unknown and pn+1, · · · , pN are unknown as well. Since the
number of missing publications is unknown, Duval and Tweedie proposed the ”Trim and
Fill” method to identify and correct for funnel plot asymmetry arising from publication bias
(Duval and Tweedie, 2000a and 2000b), in which an estimate of the number of missing stud-
ies is provided and an adjusted treatment effect is estimated by performing a meta-analysis
including the imputed studies. For the truncated p-value problem we consider here, the total
number of studies, the number of studies with truncated p-values and the p-value truncation
thresholds are all known. Therefore, investigation of the imputation of truncated p-values in
meta-analysis is different from the traditional ”publication bias” problem and has not been
studied in the meta-analysis literature, to the best of our knowledge.
In this chapter, the methods we developed mainly target on microarray meta-analysis but the
issue can happen frequently in other types of genomic meta-analysis (e.g. GWAS; Begurn et.
al. 2012). In section 2.4.3, we demonstrated an unconventional application of our methods
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to meta-analysis of liquid association. Due to the large number of triplets tested in the
three-way association, the needed p-value storage is huge. By preserving only the most
informative data by truncation, the storage burden is greatly alleviated and our imputation
methods help approximate and recover the top meta-analysis targets with little power loss.
In an on-going project, we also attempt to combine multiple genome-wide eQTL results via
meta-analysis. In eQTL, regression analysis is used to investigate the association of a SNP
genotyping and a gene expression. It is impractical to store all genome-wide eQTL p-values
as the storage space required is too large (25, 000 genes × 2, 000, 000 SNPS = 5 × 1010 p-
values). A practical solution is to record only the eQTL p-values smaller than a threshold (say
10−4) for meta-analysis, which leads to the same statistical setting as discussed in this paper.
In another project, we combine results from multiple ChIP-seq peak calling algorithms to
develop a meta-caller. Since each peak caller algorithm can only report the top peaks with
p-values smaller than a certain p-value threshold, we again encounter the same truncated
p-value problem in meta-analysis. As more and more complex genomic data are generated
and the need for meta-analysis increases, we expect the imputation methods we propose in
this chapter will find even more applications in the future.
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Table 6: Eleven pain-relevant microarray studies included in the analysis
Study Species No. of DE genes (% of total) type of threshold threshold
Ko 2002 Rat 42(0.5%) fold change 2-fold
Costigan 2002 Rat 197(2.2%) p-value 0.05
Xiao 2002 Rat 117(1.8%) fold change 2-fold
Wang 2002 Rat 166(2.4%) p-value 0.05
Sun 2002 Rat 44(0.6%) p-value 0.05
Bonilla 2002 Mouse 13(0.2%) fold change 2-fold
Kubo 2002 Mouse 53(0.6%) fold change 2-fold
Valder 2003 Rat 139(2.0%) p-value 0.05
Yang 2004 Rat 169(2.6%) p-value 0.05
Ren 2005 Rat 31(15.1%) FDR 0.05
Barr 2005 Rat 47(3.7%) FDR 0.05
Nesic 2005 Rat 36(0.1%) p-value 0.05
Rodriguez 2006 Rat 40(1%) p-value 0.00047
LaCroix-Fralish 2006 Rat 805(17.1%) p-value 0.01
Geranton 2007 Rat 74(0.2%) p-value 0.05
Griffin 2007 Rat 96(1.1%) p-value 0.01
Yukhananrov 2008 Rat 798(2.6%) p-value 0.01
Nishida 2008 Rat 51(0.3%) fold change 2-fold
Levin 2008 Rat 195(1.3%) fold-change 3-fold
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Table 7: Summary of results for patterns of pain
Fisher Stouffer
Mean 280 45
Single 57.04 (1.6228) 16.44(0.8605)
Multiple 280.36(0.8105) 77.56(0.6616)
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Table 8: Summary of pathway analysis by DAVID
280 DE 79 DE
(Fisher’s mean imputation) (Vote counting)
Category Pathway ID pval qval odds ratio pval qval odds ratio
Differentiation, GO : 0030182 ∼ 5.6e-6 0.0006 3.1 0.26 0.95 1.6
development and GO : 0045664 ∼ 1.6e-5 0.0011 4.7 0.37 0.98 1.9
projection GO : 0048666 ∼ 2.5e-6 0.0003 3.6 0.24 0.94 1.7
GO : 0051960 ∼ 6.5e-6 0.0006 4.2 0.29 0.96 1.9
GO : 0031175 ∼ 1.6e-5 0.0012 3.7 0.27 0.96 1.8
GO : 0042995 ∼ 3.6e-11 3.2e-9 3.5 0.033 0.47 1.9
GO : 0043005 ∼ 3.0e-11 3.4e-9 4.3 0.043 0.51 2.0
GO : 0030030 ∼ 1.6e-5 0.0012 3.3 0.24 0.94 1.7
Response to stimuli GO : 0009611 ∼ 3.8e-10 2.8e-7 4.3 2.7e-5 0.016 3.6
GO : 0009719 ∼ 3.2e-8 1.7e-5 3.4 0.35 0.97 1.3
GO : 0048584 ∼ 7.9e-8 2.5e-5 4.9 0.0049 0.34 3.6
GO : 0032101 ∼ 1.1e-5 0.001 4.8 0.043 0.71 2.8
Immune GO : 0050778 ∼ 4.2e-7 7.6e-5 5.9 0.018 0.57 4.0
GO : 0002684 ∼ 1.9e-6 0.0003 4.4 0.0009 0.13 4.2
GO : 0006956 ∼ 3.0e-5 0.0016 11.5 0.011 0.46 8.4
GO : 0002478 ∼ 1.3e-6 0.00022 19.0 0.00098 0.12 10.64
Inflammation GO : 0002673 ∼ 1.4e-6 0.0002 14.1 0.19 0.93 3.8
GO : 0002526 ∼ 7.1e-06 0.0007 6.7 0.012 0.48 4.4
GO : 0050727 ∼ 1.9e-5 0.0012 6.9 0.17 0.92 2.8
GO : 0006954 ∼ 1.5e-5 0.0012 4.1 0.001 0.11 3.8
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Figure 6: − log(p) comparison of the mean imputation method using truncated data with
the complete case method using complete data. Vertical line: x = 71.3. Horizontal line:
y = 72.58. Points right to vertical line are top 1, 000 triplets detected by Fisher’s complete
case method, and points above to horizontal line are top 1, 000 triplets detected by Fisher’s
mean imputation method
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3.0 ON ADAPTIVE WEIGHTING FOR P-VALUE COMBINATION
META-ANALYSIS
3.1 INTRODUCTION OF META-ANALYSIS
3.1.1 Genomic meta-analysis
Meta-analysis techniques have been widely used to combine results from multiple clinical
or genomic studies which test the same or a similar hypothesis. To combine findings from
multiple research studies, one can either combine the effect sizes directly or combine the
p-values. Since the differences in data structures and statistical hypotheses across multiple
studies may make the direct combination of effect sizes impossible or the result suspicious,
combining p-values from multiple studies is often more appealing in omics applications. The
frequently used p-value combination methods include the Fisher’s method (Fisher, 1925),
the Stouffer’s method (Stouffer et al., 1949), the logit method (Lancaster 1961) and minP
and maxP methods (Tippett 1931;Wilkinson 1951).
With the availability of tremendous genomic data in public domain, there is increased in-
terest in combining multiple studies by meta-analysis techniques. In general, the genomic
meta-analysis technique involves firstly performing combining p-values procedures for tens of
thousands of biomarkers simultaneously and then controlling the false discovery rate (FDR)
to correct the p-values for multiple comparisons. Since performing meta-analysis for large
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amount of biomarkers simultaneously is computationally demanding, there is an urgent need
to have a fast computation algorithm to reduce the computing cost. Furthermore, in order
to control the FDR well, the p-values should be evaluated by a closed form solution or ap-
proximated accurately.
In the meta-analysis of genomic studies, in order to make a stronger scientific statement, it
is more important and practical to identify those genes which are differentially expressed in
a consistent pattern across multiple studies, i.e., to detect signals in the majority of studies.
However, most combining p-value methods are targeting on the gain of statistical power by
pooling together independent studies and producing a single combined p-value to show that
at least one hypothesis is false, i.e., they are designed to test the hypothesis setting HSB.
Therefore, those combining p-values procedures can not handle the gene-specific heterogene-
ity, which makes it impossible to make a stronger scientific statement about the biological
findings.
The problem first gained attention in fMRI research (Friston, Penny and Glaser 2005) and
many other authors have tried to address this problem since then. For example, Song
and Tseng (2013) proposed the rth ordered p-value (rOP) method to test the alternative
hypothesis that the signal presents in at least a given percentage of studies. Li and Ghosh
(2014) proposed a class of meta-analysis methods based on summaries of weighted ordered
p-values (WOP). Li and Tseng (2011) proposed an adaptively weighted Fisher’s method
(AW-Fisher’s) for gene expression data analysis to test the conjunction of null hypotheses
against the alternative that at least one is false, where the weight of each study takes the
value 0 or 1 and therefore only the subset of studies yielding the most significant results were
selected for further analysis. Since expression of some important biomarkers may be altered
in a study-specific manner, 0/1 weights reflect a natural biological interpretation of whether
or not a study contributes to the statistical significance of a gene. Similar ideas such as AW-
FEM and AW-Bayesian approach were applied to GWAS meta-analysis (Han and Eskin 2012;
Bhattacharjee et al. 2012), where only the effect sizes in a subset of studies were assumed
to be non-zero in alternative hypotheses (Flutre et al., 2013). In addition to producing a
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single combined p-value, the AW-Fisher’s method also returns a vector of weights indicating
which studies are contributing to the significance of the signal. Therefore, although the AW-
Fisher’s method doesn’t target on testing for partial conjunction hypotheses, one still can
make a stronger scientific statement regarding how many studies share a consistent pattern
when the null hypothesis is rejected.
3.1.2 Adaptively weighted Fisher’s method
In this section we assume there are K studies to be combined and the effect size and cor-
responding p-value of study k is {θk, pk}, and the alternative hypothesis setting being dealt
with in this section is defined as
HSB : H0 :
K⋂
k=1
{θk = 0} versus HB :
K⋃
k=1
{θk 6= 0}. (3.1.1)
For Fisher’s method, the test statistic T Fisher is T Fisher := −2∑Kk=1 log(pk), which follows
a chi-square distribution with degree freedom of 2K (i.e., T Fisher ∼ χ22K) under the null
hypothesis. Note that the Fisher’s method only returns a p-value indicating whether the
test of null hypothesis is statistical significant or not at a given significance level α, but
gives no indication which studies contribute to the statistical significance. Although the
AW-Fisher’s method is designed to test hypothesis setting HSB too, the returned adaptive
weights indicate which studies have contributed to the statistical significance.
Figure 3.1 shows the heatmaps of gene expression for DE genes identified by Fisher’s and
AW-Fisher’s methods for three tissue mouse datasets. The heatmap of Fisher’s method
gives no indication which studies contribute to the statistical significance, but the adaptive
weights of AW-Fisher’s method grouped together the genes sharing the same gene expres-
sion pattern. Therefore, the AW-Fisher’s method can deal with gene-specific heterogeneity,
which makes it very appealing in genomic data analysis.
Now by defining the vector of true weights W ∗ as
W ∗ = (w∗1, · · · , w∗K)T with w∗k = 1(θk 6= 0) for k = 1, · · · , K, (3.1.2)
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then only the studies with nonzero effect size are included in the test statistic TW
∗
and the
tests are more powerful than T 1. However, W ∗ is unknown and can only be approximated.
Given a vector of weights W 6= 0, it holds TW ∼ χ2
2
∑K
k=1 wk
and therefore the corresponding
p-value pW is
pW = P(χ2
2
∑K
k=1 wk
≥ −2
K∑
k=1
wk log(pk)). (3.1.3)
The estimate of W ∗ and the corresponding test statistic of AW-Fisher’s method are defined
as (Li & Tseng 2011)
Wˆ := argminW 6=0{pW} and TAW := − log(min
W 6=0
{pW}). (3.1.4)
Here we show how to find the best weights by a simple toy example. Assume three studies
are to be combined and the corresponding p-values of gene 1 are (1, 1, 0.001). Table 3.1
summarizes every nonzero vector of weights and their corresponding test statistics and p-
values. It is easy to know that (0, 0, 1) are the best weights, since the p-value with respect
to these weights is the most significant.
3.1.3 Open questions of AW-Fisher’s method in Li and Tseng (2011)
It has been shown in Li & Tseng (2011) that AW-Fisher is admissible and have better power 
in a wide range of alternative hypotheses compared to minP, maxP and Fisher’s methods. 
However, there remains several important theoretical and computational questions. As de- 
scribed in Li and Tseng (2011), in order to determine the best weights, theoretically all but 
nonzero vector of weights need to be searched and compared (i.e., 2K − 1), which is very 
time-consuming in genomic studies when the number of the studies to be combined is large. 
For example, if there are p-values of 10, 000 genes across 20 studies to be combined, the 
total number of searches for the best weights will be 10, 000 × (220 − 1) = 10, 485, 750, 000. 
Furthermore, since the null distribution of the test statistic was not provided in Li and 
Tseng (2011), all the p-values were obtained by permutation tests, which further increased 
the computational burden and the p-values are not accurate and inefficient. For example, 
assuming there are 10,000 genes, in order to achieve precision to 10−12, one needs to perform
10   permutations test, which generally is impossible in practice.
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In addition to computing issues, there are also open theoretical questions. The goal of the 
AW-Fisher’s method is to assign weights 1 to the studies with non-zero effect size and 0 to 
the studies with zero effect size. Therefore one question arises naturally that if the adaptive 
weights are asymptotically consistent? Since Fisher’s method is ABO under a simplified 
Gaussian circumstance, one also wants to know if AW-Fisher is ABO.
In the sequel the solutions of two computing problems are shown in Section 3.2 and the 
answers to two theoretical questions are shown in Section 3.3.
3.2 SOLUTIONS TO TWO COMPUTING PROBLEMS
In this section the solutions to two open computational problems in Li & Tseng (2011) are
discussed. A fast algorithm of searching the adaptive weights is provided in Section 3.2.1
and an importance sampling technique is proposed to obtain accurate p-values for K ≥ 3 in
Section 3.2.2.
3.2.1 Fast searching of the adaptive weights
Note that the searching space Ω = {W : W 6= 0} contains 2K − 1 vectors of weights and
therefore searching the whole space Ω to find the adaptive weights Wˆ becomes very expensive
when K is large. The situation becomes more severe when the AW-Fisher’s method is applied
to genomic data, in which the same procedure will be repeatedly performed for thousands
of biomarkers simultaneously. In this section, based on the ordered p-values {p(i)}Ki=1, we
proposed a fast algorithm to find Wˆ by searching only K vectors of weights instead of
searching the whole exponential space. To this end, let’s firstly rewrite Ω as Ω =
⋃K
k=1 Ωk
with Ωk = {W :
∑K
j=1wj = k} for k = 1, 2, · · · , K, then it holds Wˆ = minW∈Ω{pW} =
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min1≤k≤K{minW∈Ωk{pW}}.
Lemma 3.2.1. Denote {p(1), · · · , p(K)} as the ordered version of {p1, · · · , pK}, then for
k = 1, 2, · · · , K, it holds
−2
k∑
i=1
log(p(i)) = max
W∈Ωk
{−2
K∑
i=1
wi log(pi)}.
Proof. The proof is trivial.
Without loss of generality, denote by W k the vector of weights such that
−2
K∑
j=1
wkj log(pj) = −2
k∑
j=1
log(p(j)),
then Lemma 3.2.1 demonstrates that the test statistic involving the first k ordered p-values
will generate the most significant p-value in Ωk, therefore in each Ωk, only one vector of
weights W k has to be considered for further searching, which implies that instead of searching
the whole space Ω, it is enough to search only K vectors of weights to find the adaptive
weights Wˆ , i.e.,
Corollary 3.2.2. TAW satisfies
TAW = − log( min
1≤k≤K
{pWk}) and Wˆ = arg min
1≤k≤K
{pWk}. (3.2.1)
The proposed fast algorithm contains two steps: firstly sorting K p-values and then searching
K vectors of weights. The complexity of sorting a vector of K p-values varies from O(K) to
O(K log(K)) and to O(K2) by different sorting algorithms, and the complexity of searching
K vectors of nonzero weights is of the order O(K). Therefore, the fast searching algorithm
proposed in this section reduces the computational complexity fromO(2K) to at mostO(K2),
which saves a lot of computing time when K is large (see Table 3.2 for comparison).
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3.2.2 Computation of P(TAW > − log(t))
Recall that TAW = − log(t), where t = min1≤k≤K{pWk} = pWˆ . Let tj = exp(−χ−22j (t)/2) and
Tj =
∏j
i=1 P(i), then
P(TAW > − log(t)) = P(∪Kj=1Tj < tj). (3.2.2)
Since the joint distribution of P(i), i = 1, . . . , K is f(p1, . . . , pK) = K!, 0 ≤ P(1) ≤ P(2) ≤
· · · ≤ P(K) ≤ 1, it is possible to estimate P (TAW > − log(t)) analytically. Without loss of
generality, let’s denote by Aj the event {Tj < tj}, then P(TAW > − log(t)) can be rewritten
as
P(TAW > − log(t)) = P(∪Kj=1Aj) = P(A1) +
K∑
k=2
P(Ak ∩ (∪k−1j=1Acj)), (3.2.3)
where Acj is the complementary event of Aj. The above formula provides an analytical way
to compute the p-value P(TAW > − log(t)). For example, when K = 2,
P(TAW > − log(t)) = P(∪Kj=1Tj < tj) = 1−P(T1 ≥ t1, T2 ≥ t2)
= 1−
∫ 1
t1
∫ 1
t2/p11
2 · 1(p1 ≤ p2)dp2dp1 = 1−
∫ 1
t1
∫ 1
max{t2/p11,p1}
2dp2dp1
= 1−
∫ 1
t1
2[1−max{t2/p1, p1}]dp1.
In the case t21 ≥ t2,∫ 1
t1
2[1−max{t2/p1, p1}]dp1 =
∫ 1
t1
2{1− p1}dp1 = (1− t1)2.
If t21 < t2, ∫ 1
t1
2[1−max{t2/p1, p1}]dp1 =
∫ 1
t1
2dp1 −
∫ 1
√
t2
2p1dp1 −
∫ √t2
t1
2t2/p1dp1
= 2(1− t1)− (1− t2)− t2 log(t2/t21) = 1− t1 + t2 − t2 log(t2/t21).
Therefore, for K = 2, the p-value P(TAW > − log(t)) for given observed test statistic− log(t)
can be computed analytically by
P(TAW > − log(t)) =
2t1 − t
2
1 t
2
1 ≥ t2
t2 log(t2/t
2
1) + 2t1 − t2, t21 < t2
. (3.2.4)
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Theoretically, P(TAW > − log(t)) can be computed analytically for any K ≥ 2. However,
the computation of P(Ak∩(∪k−1j=1Acj)) involves the evaluation of a k-fold integral and the inte-
gration domain becomes very complicated for k ≥ 3, which makes the derivation of the close
form of P(Ak ∩ (∪k−1j=1Acj)) very tedious and fallible. Hence in this paper, we propose to use
importance sampling technique to obtain a numerical approximation of P(TAW > − log(t)).
Importance sampling is a method to reduce variance when using Monte Carlo sampling
method. The idea behind importance sampling is to draw samples from a different distribu-
tion rather than the distribution of interest and assign a weight to each sample based on the
two distributions. This technique is very useful when evaluating an unknown distribution or
obtaining the mean of a certain function.
To evaluate P(TAW > − log(t(p1, . . . , pK))), we use beta-distribution to draw Pi so that we
can ”over-sample” those small p-values that result in a large − log(t).
P(TAW > − log(t)) = E[1(TAW > − log(t))]
=
∫
1(TAW > − log(t)) f(t
AW )
f ∗(tAW )
f ∗(tAW )dtAW
= E∗[1(TAW > − log(t)) ∗W (TAW ])
where W (·) = f(·)/f ∗(·) and E∗(·) is the expectation with respect to f ∗(·).
Under the null hypothesis, Pi ∼ U(0, 1), so the joint distribution of {Pi}Ki=1 is f(p1, . . . , pk) =
1. If we instead using Beta(1, a) distribution to draw Pi, the joint distribution of P1, . . . , PK
will be f ∗(p1, . . . , pK) = (a − 1)K(p1 · · · pK)a−1. Optimal a should be chosen such that
P(TAW > − log(t)) has the smallest variance for a given test statistic − log(t). For a given
K, we predefine test statistics t1, · · · , t20. For each ti, i = 1, · · · , 20, we select different a and
use enough number of samples n such that sd(pˆ) < pˆ
100
.
In Figure 3.2, the p-values in log-scale for K = 3 and K = 20 are presented and it can be
seen that when − log(t) is large, the p-values in log-scale are almost on a straight line, which
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implies that the p-value of a new test statistic may be obtained by interpolation. Therefore,
for a given K ≥ 3, one can generate a table, where the first column are pre-selected test
statistics − log(t) and the second column are the corresponding p-values of the test statistics
computed by importance sampling technique. Therefore, when a new test statistic comes,
we provide accurate p-value using monotone cubic spline interpolation in log-scale. We will
provide an R-package that can generate p-values for K = 2, 3, · · · , 1000.
3.3 ASYMPTOTICAL PROPERTIES OF THE AW-FISHER’S METHOD
In the last section, a fast algorithm of searching the adaptive weights and an accurate and
fast method of computing the p-value P(TAW > − log(t)) are given, which make the AW-
Fisher’s method more practical and very appealing in real data analysis. In this section we
will investigate some asymptotical properties of the AW-Fisher’s method, such as consistency
of the adaptive weights and the asymptotical Bahadur optimality (ABO).
3.3.1 Assumptions and notations
Suppose we have K independent studies for testing H0 : θ = 0 with sample size nk and
p-value pk for k = 1, · · · , K. Assume that for each k = 1, · · · , K, the statistical test for
study k has exact slope ck(θ), i.e.,
− 2
nk
log(pk)→ ck(θ) as nk →∞.
Obviously by definition, ck(θ) is always non-negative. This assumption states that when
ck(θ) is positive, the p-value pk will decay to 0 exponentially as n goes to infinity.
Furthermore, we assume
lim
n→∞
nk
n
= λk for k = 1, · · · , K,
where n = 1
K
∑K
k=1 nk.
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Obviously n is the averaged sample size and it holds
∑K
k=1 λk = K and − 2n log(pk)→ λkck(θ).
This assumption guarantees no study will dominate the others and the sample sizes of all
the studies will tend to infinity at the same rate.
3.3.2 Consistency of the estimated weights Wˆ
In this section we will show that the consistency of the estimated adaptive weights Wˆ, i.e.,
Wˆ → W∗ with probability one when the averaged sample size n tends to infinity. To this
end, we first give the following lemmas.
Without loss of generality, let’s assume the 100(1 − α)% quantile of χ2m is χ−2m (α), i.e.,
P(χ2m ≥ χ−2m (α)) = α. Obviously χ−2m (α) → ∞ as α → 0. The next lemma states that
χ−22k+2l(α) > χ
−2
2k (α) for k, l ≥ 1 and small α.
Lemma 3.3.1. For small enough α > 0 and k, l ≥ 1, it holds
χ−22k+2l(α) > χ
−2
2k (α). (3.3.1)
Proof. Note that
P(χ22k+2l > χ
−2
2k (α)) =
∫ ∞
χ−22k (α)
xk+l−1e−
x
2
2k+lΓ(k + l)
dx =
∫ ∞
χ−22k (α)
(
x
2
)l
Γ(k)
Γ(k + l)
xk−1e−
x
2
2kΓ(k)
dx
> (
χ−22k (α)
2
)l
Γ(k)
Γ(k + l)
∫ ∞
χ−22k (α)
xk−1e−
x
2
2kΓ(k)
dx = (
χ−22k (α)
2
)l
Γ(k)
Γ(k + l)
P(χ22k > χ
−2
2k (α))
= (
χ−22k (α)
2
)l
Γ(k)
Γ(k + l)
α.
Therefore, given k, l ≥ 1, there always exists α > 0 such that (χ−22k (α)
2
)l Γ(k)
Γ(k+l)
> 1 and thus
P(χ22k+2l > χ
−2
2k (α)) > α, which implies χ
−2
2k+2l(α) > χ
−2
2k (α).
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Lemma 3.3.1 shows that χ−22k+2l(α) > χ
−2
2k (α) holds for some small α > 0. Furthermore, the
following lemma shows that in fact χ−22k+2l(α)− χ−22k (α) will tend to infinity as α→ 0.
Lemma 3.3.2. Given significance level α > 0 and integers k, l ≥ 1, it holds
42l := χ−22k+2l(α)− χ−22k (α)→∞ as α→ 0.
Proof. Recall that the cumulative distribution function of χ2k is F (x, k) =
γ( k
2
,x
2
)
Γ( k
2
)
, where γ(·, ·)
is the lower incomplete Gamma function. Therefore, it holds
α = P(χ22k ≥ χ−22k (α)) = 1−
γ(k,
χ−22k (α)
2
)
Γ(k)
= e−
χ−2
2k
(α)
2
k−1∑
j=0
(
χ−22k (α)
2
)j
j!
.
Similarly, it holds
α = P(χ22k+2l ≥ χ−22k+2l(α)) = 1−
γ(k + l,
χ−22k+2l(α)
2
)
Γ(k + l)
= e−
χ−2
2k+2l
(α)
2
k+l−1∑
j=0
(
χ−22k+2l(α)
2
)j
j!
.
By setting χ−22k+2l(α) = χ
−2
2k (α) +42l, it holds 42l > 0 for small enough α > 0. Furthermore,
it is easy to show that
e−
42l
2 =
∑k−1
j=0
(
χ−2
2k
(α)
2
)j
j!∑k+l−1
j=0
(
χ−2
2k
(α)+42l
2
)j
j!
→ 0 as α→ 0,
which proves the lemma.
Recall that 42l = χ−22k+2l(α) − χ−22k (α) is the discrepancy of 100(1 − α)% quantiles between
χ22k+2l and χ
2
2k. Therefore, Lemma 3.3.2 states that when α is small, in order for χ
2
2k+2l to
preserve the same significant level α as χ22k does, the l newly included studies should have
very small p-values {pj}k+lj=k such that −2
∑k+l
j=k log(pj) ≥ χ−22k+2l(α)−χ−22k (α) . Next theorem
demonstrates that the adaptive weights Wˆ of AW-methods are asymptotically consistent.
57
Theorem 3.3.3. Wˆ → W ∗ as n → ∞, i.e. all and only the studies with non-zero effect
sizes will contribute to the test statistic, and the convergent rate of Wˆ is of the order O(n−1).
Proof. Let − 2
n
∑i
j=1 log(pj) →
∑i
j=1 λjcj(θ) = Ci for i = 1, . . . , K. Suppose i studies have
weight 1.
Firstly, if θi+1 6= 0,
lim
n→∞
1− χ22i(−2
∑j
j=1 log(pj))
1− χ22(i+1)(−2
∑i+1
j=1 log(pj))
→ lim
n→∞
1− χ22i(2nCi)
1− χ22(i+1)(2nCi+1)
→ lim
n→∞
iCi−1i
iCi−1i+1 + nC
i
i+1
exp{n(Ci+1 − Ci)} → ∞
since Ci+1−Ci = λi+1ci+1 > 0 and 1−χ22i(2nCi) = P(χ22i > 2nCi). Therefore study i+1 will
eventually get a weight 1. Therefore, we have shown that if θi+1 6= 0, including the (i+ 1)th
study into analysis results in a more significant p-value which converges to 0 at accelerated
convergent rate ni+1 exp{−ni+1ci+1(θ)}.
Secondly, if there exists a study with zero effect size that has a weight 1. Without loss of
generality, let θi = 0. In order to have weight 1 for study i, one must have
1− χ22i(−2
i∑
j=1
log pj) ≤ 1− χ22(i−1)(−2
i−1∑
j=1
log pj).
Since
χ22i(t) = 1−
i−1∑
j=0
1
j!
(
t
2
)j
exp{− t
2
},
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we have
i−1∑
j=0
1
j!
(
−
i∑
j=1
log pj
)j
exp{
i∑
j=1
log pj} ≤
i−2∑
j=0
1
j!
(
−
i−1∑
j=1
log pj
)j
exp{
i−1∑
j=1
log pj}.
Thus,
pi = exp{log pi} ≤
∑i−2
j=0
1
j!
(
−∑i−1j=1 log pj)j∑i−1
j=0
1
j!
(
−∑ij=1 log pj)j → n
−1(i− 1)Ci−2i−1C−i+1i → n−1(i− 1)C−1i ,
as n → ∞, i.e. pi ≤ n−1(i − 1)C−1i → 0. Therefore, eventually, no studies with zero effect
size will have weight 1. Now we have proven that the adaptive weights are asymptotically
consistent. Since the convergent rate of the adaptive weights depends on how fast one assigns
weights 0 to the studies with zero effect size, one concludes from the above discussion that
the convergence rate of the adaptive weights is of order O(n−1).
3.3.3 The asymptotic Bahadur optimality (ABO) of AW-Fisher’s method
In last subsection we proved that the adaptive weights are asymptotically consistent. In
this subsection we will investigate the optimality of the AW-Fisher’s method. One way to
compare the performance of different tests is the Bahadur relative efficiency (Bahadur 1967),
which is defined as the ratio of the exact slopes of different statistical tests and therefore
the test with larger exact slope is viewed as superior. In this paper we will use the Bahadur
relative efficiency as our primary index of comparing combined p-value procedures. In fact,
by assumption − 2
n
log(pi) → ci(θ) as n → ∞, the exact slope measures how quickly the p-
value of a test converges to 0 as n tends to infinity when θ 6= 0, and therefore it can be used
to compare the performances of different tests. Assuming there are two tests for testing the
same hypotheses and have exact slopes c1(θ) and c2(θ) respectively, then the ratio c1(θ)/c2(θ)
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is the exact Bahadur efficiency of test 1 relative to test 2, and c1(θ)/c2(θ) > 1 implies that
p1 converges to 0 faster than p2 for large enough n. Note that the exact Bahadur efficiency
is asymptotic property of two tests, so c1(θ)/c2(θ) > 1 doesn’t imply p1 < p2 for small n.
Lemma 3.3.4. For θ = 0, it holds − 2
n
log(p)→ 0 with probability one, i.e., if the effect size
is 0, the exact slope c(θ) of the statistical test is 0.
Proof. Recall that for θ = 0, the p-value p is distributed uniformly on the interval (0, 1). So
it holds
E(− 2
n
log(p)) = − 2
n
∫ 1
0
log(x)dx =
2
n
→ 0. (3.3.2)
Since − 2
n
log(p) is always positive for p ∈ (0, 1), one concludes that
− 2
n
log(p)→ 0, (3.3.3)
i.e., c(0) = 0.
Lemma 3.3.4 states that non-significant studies have no impact on the exact slope of com-
bined p-value procedures which fits our intuition.
Littel and Folk had shown that given K independent studies with p-values, sample sizes and
exact slopes {(pk, nk, ck(θ))}Kk=1 respectively, the exact slope of Fisher’s method is cFisher(θ) =∑K
k=1 λkck(θ) (Littel and Folk, 1971) and the Fisher’s method is ABO, i.e., cFisher(θ) is the
largest among all combining p-value procedures (Littel and Folk, 1973), under the assumption
θk ≡ θ 6= 0. This assumption is very stringent, since the global null hypothesis H0 :⋂K
k=1{θk = 0} will be rejected if at lease one θk is nonzero. In this paper we will consider the
alternative hypothesis Ha :
⋂r
k=1{θk ≡ θ 6= 0},
⋂K
j=r+1{θj = 0}. Therefore in this case, when
the null hypothesis is false, the exact slope of Fisher’s method is cFisher(θ) =
∑K
k=1 λkck(θ) =
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∑r
k=1 λkck(θ), which is still ABO. In the sequel we will investigate if the AW-Fisher’s method
is ABO under this assumption.
In the sequel we will calculate cAW (θ). Next theorem shows that cAW (θ) = cFisher(θ), i.e.,
the AW-Fisher’s method is ABO.
Theorem 3.3.5. It holds cAW (θ) = cFisher(θ), i.e., the AW-Fisher’s method is ABO.
Proof. Let {p′1, . . . , p′j} is a subset of {p1, . . . , pK} with size j for j = 1, . . . , K, then for a
given test statistic − log(t), it holds
P(TAW ≥ − log(t)) = P(
K⋃
j=1
{−2
j∑
i=1
log(P ′i ) ≥ χ−22j (t))})
≤
K⋃
j=1
P({−2
j∑
i=1
log(P ′i ) ≥ χ−22j (t)})
= (2K − 1)t
as n goes to infinity.
Since the adaptive weights are consistent, it holds
lim
n→∞
− 2
n
log(t) = lim
n→∞
− 2
n
log(1− χ22r(−2
r∑
i=1
log(pi))) =
r∑
i=1
λici(θ),
we have
lim
n→∞
− 2
n
log(P(TAW ≥ − log(t))) ≥ lim
n→∞
− 2
n
{log(t) + log(2K − 1)} =
r∑
i=1
λici(θ).
On the other hand, since
P(TAW ≥ − log(t)) ≥ P({−2
r∑
i=1
log(Pi) ≥ χ−22r (t)}) = t,
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by utilizing the consistency of the adaptive weights again, we have
lim
n→∞
− 2
n
log(P(TAW ≥ − log(t))) ≤ lim
n→∞
− 2
n
log(t) =
r∑
i=1
λici(θ),
i.e., cAW (θ) = cFisher(θ) and so AW-Fisher’s method is ABO too under the alternative
hypothesis Ha :
⋂r
k=1{θk ≡ θ 6= 0},
⋂K
j=r+1{θj = 0}.
3.4 SIMULATIONS
3.4.1 ABO of AW-Fisher’s method
In this subsection, the following hypotheses H0 : θ1 = θ2 = 0 vs. HA : θ1 = 0.3, θ2 = 0 
for K = 2 and H0 : θ1 = θ2 = θ3 = 0 vs. HA : θ1 = 0.3, θ2 = θ3 = 0 for K = 3 
were tested. We expect the estimated exact slopes of AW-Fisher’s method and the Fisher’s 
method are similar, provided the sample sizes are large enough. The sample sizes were cho- 
sen as {20, 30, 50, 75, 100, 125, 150, 175, 200, 250, 300, 350,
400, 450, 500, 750, 1000, 2000, 3000, 4000, 5000, 7500, 10000, 12500, 15000, 17500, 20000}. For 
each sample size, 5000 simulations were performed and the mean exact slopes were cal- 
culated.
Figure 3.3 shows clearly that the AW-Fisher’s method is ABO, since the exact slopes of 
AW-Fisher’s method and Fisher’s method converge as n tends to infinity.
3.4.2 Comparison of AW-Fisher and Fisher’s method
In this subsection, K = 20 independent studies are combined, in which 10 studies have
zero effect sizes and 10 studies have nonzero effect sizes. Figure 3.4 compares the p-values
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of AW-Fisher and Fisher’s method and the plot shows that in most cases the AW-Fisher’s 
method will produce more significant p-values.
Table 3.1 summarizes the powers that AW-Fisher and Fisher’s method achieve at different 
significance levels α. The results shows that AW-Fisher is powerful than Fisher’s method.
3.4.3 Accuracy of importance sampling algorithm
In this chapter, we proposed an importance sampling algorithm to obtain accurate p-values 
for K ≥ 2. Since the close form of p-value calculation is available for K = 2, in this section, we 
will compare the p-values generated by the close form and by the importance sampling 
algorithm for K = 2 for validation. Figure 3.5 shows the scatter plots of log-scaled p-values 
generated by close form and importance sampling algorithms for three hypotheses setting 
where 0, 1 or 2 studies have non-zero effect sizes. The plots indicate that the importance sam- 
pling algorithm can reach to the accuracy of 10−30 which validates our numerical algorithm for 
p-value approximation.
3.5 DISCUSSION AND CONCLUSION
The AW-Fisher’s method proposed in Li & Tseng 2011 possesses good properties such as
admissibility and better overall power compared to minP, maxP and Fsiher’s method. Fur- 
thermore, the adaptive weights give the indication which studies contribute to the statistical
significance, which makes it more appealing in genomic data analysis.
In genomic meta-analysis, it is very crucial to have a fast and accurate algorithm to reduce the
computing cost and increase the reliability of the results. However, in Li & Tseng 2011, the
computational complexity of searching the adaptive weights is exponential and the p- values
were evaluated by permutation tests, which is inaccurate and inefficient. Furthermore, some
asymptotical properties such as the consistency of the weights and the asymptotic Bahadur 
optimality (ABO) remain open in Li & Tseng (2011).
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In this chapter, we investigated the theoretical questions and concluded that the adaptive
weights are consistent and the AW-Fisher is also ABO. Furthermore, based on order statistic
technique, we successfully reduce the complexity of searching the best weights from expo-
nential to linear. Now the total cost of the fast searching algorithm involves sorting the
vector of K p-values and searching k non-zero vector of weights, which results in an overall
complexity of at most O(K2) depending on the sorting algorithm used. The close form of
the p-value computation is derived for K = 2, and for K ≥ 3, an importance sampling
algorithm was proposed to evaluate the p-values. Since the p-values are almost linear to
large test statistics in log-scale, for each K ≥ 3, a table containing a column of test statistics
and their corresponding p-values can be generated in a very accurate manner and then saved
for later use. When a new statistic is coming, one can compute the corresponding log-scaled
p-value by cubic interpolation, which is very efficient and accurate.
Since the AW-Fisher has good theoretical properties and the computation of the p-values is 
fast and accurate, we expect it will find more applications in the future.
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Fisher’s method AW method 
Figure 7: Heatmaps of gene expressions for DE genes identified by Fisher’s and AW-Fisher’s
methods in the mouse energy metabolism datasets.
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Table 9: Toy example of finding the adaptive weights
Weights Weighted statistic Null distribution p-value
(1,1,1) 13.82 χ26 0.032
(1,1,0) 0 χ24 1
(1,0,1) 13.82 χ24 0.008
(0,1,1) 13.82 χ24 0.008
(1,0,0) 0 χ22 1
(0,1,0) 0 χ22 1
(0,0,1) 13.82 χ22 0.001
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Table 10: Comparison of complexities 2K − 1 vs. K. Total cost: sorting (at most O(K2))
and linear searching (O(K))
K/Methods exponential searching Linear searching
2 3 2
3 7 3
4 15 4
5 31 5
6 63 6
7 127 7
8 255 8
9 511 9
10 1023 10
11 2047 11
12 4095 12
13 8191 13
14 16383 14
15 32767 15
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Figure 8: p-values of AW-Fisher’s method in log scale for K = 3 and K = 20
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Figure 9: Comparison of the approximated exact slopes for AW-Fisher and Fisher’s method
for K = 2 and K = 3. Only the first study has non-zero effect size 0.3.
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Figure 10: Comparison of the p-values of AW-Fisher and Fisher’s method
Table 11: Powers of AW-Fisher and Fisher’s method at different significance levels α
Method/α 10−3 10−5 10−7 10−9
AW 0.98 0.93 0.86 0.77
Fisher 0.97 0.91 0.82 0.72
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Figure 11: Comparison of the p-values in log-scale. Case 1: P1, P2 ∼ Uniform(0, 1); Case
2: P1 ∼ Uniform(0, 1), P2 ∼ Beta(1, 1020); Case 3: P1 ∼ Beta(1, 1015), P2 ∼ Beta(1, 1020).
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4.0 CONCLUSION AND FUTURE WORKS
4.1 CONCLUSION
The rapid development of high-throughput experimental technology in the past decade has
made the generation of genomic data more and more affordable. However, the sample size in
each individual study is usually small and therefore using meta-analysis to combine multiple
genomic studies can increase the statistical power and make it possible to draw a stronger
scientific statement. In this dissertation, I proposed a series of tools for univariate meta-
analysis methods which can be easily applied to genomic data.
In chapter 2, I proposed three imputation methods for evidence aggregation p-value com-
bination methods. In order to apply the conventional p-value combination methods such
as the Fisher’s method or the Stouffer’s method, all the p-values should be known in ad-
vance. However, in many medical publications, usually only a partial DE gene list was
reported with respect to a given p-value threshold, which results in the artificially ”cen-
sored” p-values and the conventional meta-analysis methods can not be applied directly to
those ”censored” p-values. Based on the null hypothesis that the true effect size is zero and
thus the p-value follows uniform distribution on [0, 1], I proposed three imputation meth-
ods (the mean imputation, the single random imputation and the multiple imputation) and
imputed the ”censored” p-values accordingly. The conventional evidence aggregation meta-
analysis methods now can be applied to the imputed p-values. In order to compute the
p-values accurately, the analytical null distributions of the test statistic were derived for
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the mean imputation and the single random imputation methods and the asymptotical null
distribution was derived for the multiple imputation. The proposed imputation methods
were compared with the available case method for simulated expression profiles and two
real prostate cancer and MDD data. The results indicate that the proposed imputation
methods have higher DE gene detection capacity than the available method and among the
imputation methods, the mean imputation and the multiple imputation methods are more
powerful than the single random imputation method. The proposed imputation methods
were also applied to two real examples in colorectal cancer and pain data and the results
indicate that both mean imputation and multiple imputation performed among the best in
terms of detection capacity and biological validation by pathway analysis. The mean impu-
tation method is recommended in practice, since it possesses similar detection capacity as
the multiple imputation method does and it requires lower computational burden.
In chapter 3, I revisited the AW-Fisher’s method. The AW-Fisher’s method aims to assigning
weight 1 to the studies with non-zero effect size and assigning 0 to the studies with zero effect
size. Therefore the estimated adaptive weights provide insights on which studies contribute
to the statistical significance. In chapter 3, I investigated some asymptotical properties of
the AW-Fisher’s method such as the consistency of the adaptive weights and asymptotical
Bahadur optimality (ABO). Furthermore, two computing issues were discussed. Firstly, I
provided a fast algorithm basing on ordered p-values to search for the adaptive weights and
the computational complexity of total cost is reduced from O(2K) to at most O(K2) (at
most O(K2) for sorting the p-values and O(K) for searching the best weights). Secondly,
I provided a closed form to compute the p-values for K = 2 and an importance sampling
algorithm was proposed to compute the p-values for K ≥ 3. Since for each given K ≥ 3, the
p-values in log-scale are almost linear for large test statistic, we provided a fast algorithm to
compute the p-value for a given test statistic. We firstly generate a table of some preselected
test statistics and their corresponding p-values by importance sampling algorithm, then for
any new test statistic we approximate the p-value by monotone cubic interpolation. The
fast algorithm was compared to the closed form for K = 2 and the results indicate that
the numerical approximation can reach the precision of 10−30 which is accurate enough in
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practice. The fast algorithms make the AW-Fisher’s method very useful and appealing in
practice.
4.2 FUTURE WORKS
In the future, I intend to further extend my current work in several ways, including method-
ology and software.
Firstly, I will polish my R codes and make it easy to use. An R package will be developed
for the methods discussed in this dissertation. And the package will be submitted to the
comprehensive R archive network (CRAN, http://cran.r-project.org).
Secondly, I will extend my methodologies into the vertical integration of multiple data types.
So far, I mainly focus on the horizontal genomic meta-analysis, i.e., combining multiple rele-
vant studies (e.g. microarray or GWAS) to increase statistical power. It should be noted that
recent technology has made it possible to simultaneously perform multi-platform genomic
profiling of biological samples and produce multi-dimensional genomic data. Such data de-
scribe the biological properties of the same cohort from different angles and it provides great
opportunity to study the coordination between regulatory mechanisms on multiple levels.
With the rapid decline of sequencing costs, such data will soon accumulate rapidly and the
need for integrating the information contained in the multi-dimensional genomic data will
increase. Since existing tools are designed for one-dimensional or at most two-dimensional
genomic data, novel methods, for example, vertical genomic integrative analysis, for ana-
lyzing multi-dimensional datasets for effective information extraction and hypothesis testing
should be developed.
Unlike horizontal genomic meta-analysis, the vertical genomic integrative analysis, which
integrates multiple studies that measure multiple dimension of genetic information of the
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same cohort (e.g. transcription, genotyp- ing, copy number variation, methylation, miRNA
etc), is more challenging. This is a relatively new research filed and it contains rich topics
and open questions waiting for researchers to solve. In future research I will devote myself
to methodology research of the vertical genomic integrative analysis and their applications.
74
     BIBLIOGRAPHY
[1] Benjamini, Y. and Hochberg, Y. (1995). Controlling the false discovery rate: a
practical and powerful approach to multiple testing. Journal of the Royal Statistical
Society Series B, 57: 289-300.
[2] Benjamini, Y. and Yekutieli, D. (2001). The control of the false discovery rate in
multiple testing under dependency. Annals of Statistics, 29: 1165-1188.
[3] Berger R.L. (1982). Multiparameter hypothesis testing and acceptance sampling.
Technometrics, 24: 295-300.
[4] Bertucci F., Salas S., Eysteries S., et al. (2004). Gene expression profiling of colon
cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene,
23: 1377-91.
[5] Bianchini M., Levy E., Zucchini C., et al. (2006). Comparative study of gene expres-
sion by cDNA microarray in human colorectal cancer tissues and normal mucosa. Int
J Oncol, 29: 83-94.
[6] Birnbaum A. (1954). Combining independent tests of significance. Journal of the
American Statistical Association, 49: 559-574.
[7] Birnbaum A. (1955). Characterizations of complete classes of tests of some multipara-
metric hypothesis, with applications to likelihood ratio tests. ANN. Math. Statist.,
26: 21-36.
75
[8] Bellot G.L., Tan W.H., Tay L.L., Koh D. et al. (2012). Reliability of tumor primary
cultures as a model for drug response prediction: expression profiles comparison of
tissues versus primary cultures from colorectal cancer patients. J Cancer Res Clin
Oncol, 138(3): 463-482.
[9] Borovecki F. et al (2005). Genome-wide expression profiling og human blood reveals
biomarkers for huntingtons disease. Proceedings of the National Academy of Sciences,
102: 11023-11028.
[10] Cardoso J. et al. (2007). Expression and genomic profiling of colorectal cancer.
Biochimica et Biophysica Acta-Reviews on Cancer, 1775: 103-137.
[11] Chan S.K., Griffith O.L., Tai I.T. and Jones S.J.M. (2008). Meta-analysis of colorec-
tal cancer gene expression profiling studies identifies consistently reported candidate
biomarkers. Cancer Epidemiol Biomarkers Prev, 17(3): 543-552.
[12] Chang L.C., Lin H.M., Sibille E. and Tseng G.C. (2013). Meta-analysis methods for
combining multiple expression profiles: comparisons, statistical characterization and
an application guideline. BMC Bioinformatics, 14: 368.
[13] Choi J.K. et al. (2003). Combining multiple microarray studies and modeling inter-
study variation. Bioinformatics, 19: 84-90.
[14] Choi H. et al. (2007). A latent variable approach for meta-analysis of gene expression
data from multiple microarray experiments. BMC Bioinformatics, 8: 364-383.
[15] Cooper H.M. and Hedges L.V. (Eds.) (1994). The handbook of research synthesis.
New York: Russell Sage Foundation.
[16] Croner RS, Foertsch T, Brueckl WM, et al. (2005). Common denominator genes
that distinguish colorectal carcinoma from normal mucosa. Int J Colorectal Dis, 20:
353-362.
76
of testing and adjusting for publication bias in meta-analysis. Biometrics, 56(2):
455-463.
[18] Duval S. and Tweedie R.L. (2000b). A nonparametric ”Trim and Fill” method of
accounting for publication bias in meta-analysis. JASA, 95(1): 89-98.
[19] Fisher R.A. (1932). Statistical methods for research workers. Edinburgh, Oliver &
Boyd, 4th edition.
[20] Fleiss J.L. (1994). Measures of effect size for categorical data. In H. Cooper & L. V.
Hedges (Eds.),The handbook of research synthesis (pp. 245-260), New York: Russell
Sage Foundation.
[21] Folks J.L. (1984). Combination of independent tests. In Handbook of statistics 4. Non-
parametric methods, P.R. Krishnaiah and P.K. Sen (eds):New York, North-Holland
[22] Gorlov I.P. et al. (2009). Candidate pathways and genes for prostate cancer: a meta-
analysis of gene expression data. BMC Medical Genomics, 2:48.
[23] Grade M., Hormann P., Becker S., et al. (2007). Gene expression profiling reveals a
massive, aneuploidy-dependent transcriptional deregulation and distinct differences
between lymph node-negative and lymph node-positive colon carcinomas. Cancer
Res, 67:41-56.
[24] Griffith O.L., Jones S.J.M. and Wiseman S.M. (2006). Meta-analysis and meta-review
of thyroid cancer gene expression profiling studies identifies important diagonstic
biomarkers. J. Clin. Oncol., 24:5043-51.
[25] Hedges L.V. and Olkin I. (1980). Vote-counting methods in research synthesis. Psy-
chological Bulletin, 88:359.
[26] Hedges L.V. and Olkin I. (1985). Statistical methods for meta-analysis. Academic
Press Inc.: Orlando, Florida.
77
[17] Duval S. and Tweedie R.L. (2000a). Trim and fill: a simple funnel-plot-based method
[27] Hedges L.V. and Vevea J.L. (1998). Fixed- and random-effects models in meta-
analysis. Psychological Methods, 3:486-504.
[28] Hedges L.V. (2007). Meta-analysis. In C. R. Rao & S. Sinharay (Eds.), Handbook of
statistics: Vol. 26. Psychometrics (pp.919-953), New York: Russell Sage Foundation.
[29] Hunter J.E. and Schmidt F.L. (2000). Fixed effects vs. random effects meta-analysis
models: Implications for cumulative research knowledge. International Journal of
Selection and Assessment, 8:275-292.
[30] Ioannidis J.P.A., Allison D.B., Ball C.A. and et. al. (2009). Repeatability of published
microarray gene expression analysis. Nature Genetics, 41:149-155.
[31] Jiang X., Tan J., Li J., Kivima¨e S. et al. (2008). DACT3 is an epigenetic regulator of
Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone
modifications. Cancer Cell, 13(6):529-41.
[32] Kim H., Nam S.W., Rhee H., et al. (2004). Different gene expression profiles be-
tween microsatellite instability-high and microsatellite stable colorectal carcinomas.
Oncogene, 23: 6219-25.
[33] Kwon H.C., Kim S.H., Roh M.S., et al. (2004). Gene expression profiling in lymph
node-positive and lymph node-negative colorectal cancer. Dis Colon Rectum, 47:
141-152.
[34] LaCroix-Fralish M.L. et. al.. (2011). Patterns of pain: Meta-analysis of microarray
studies of pain. Pain, 152: 1888-1898.
[35] Lancaster H. (1961). The combination of probabilities: an application of orthonormal
functions. Australian Journal of Statistics, 3: 20-33.
[36] Littell C.L. and Floks J.L.. (1971). Asymptotic Optimality of Fisher’s Method
of Combining Independent Tests. Journal of the American Statistical Association,
66(336): 802-805.
78
[37] Littell C.L. and Floks J.L.. (1973). Asymptotic Optimality of Fisher’s Method of
Combining Independent Tests II. Journal of the American Statistical Association,
68(341): 193-194.
[38] Lau J., Antman E.M. and Jimenez-Silva J. et. al. (1992). Cumulative meta-analysis
of therapeutic trials for Myocardial infarction. The new England Journal of Medicine,
327:248-254.
[39] McCarley R.W., Wible C.G., Frumin M., Hirayasu Y., Levitt J.J., Shenton M.E.
(2001). Why vote-count reviews don’t count [letter to the editor]. Biological Psychi-
atry, 49: 161-163.
[40] Li J. and Tseng G.C. (2011). An adaptively weighted statistic for detecting differential
gene expression when combining multiple transcriptomic studies. Annals of Applied
Statistics, 5(2A):994-1019.
[41] Littell R.C. and Folks J.L.(1971). Asymptotic optimality of Fisher’s method of com-
bining independent tests. Journal of the American Statistical Association, 66: 802-
806.
[42] Littell R.C. and Folks J.L. (1973). Asymptotic optimality of Fisher’s method of
combining independent tests ii. Journal of the American Statistical Association, 68:
193-194.
[43] Moreau Y. et al. (2003). Comparison and meta-analysis of microarray data: from
the bench to the computer desk. Trends in Genetics, 19: 570-577.
[44] Olkin I. and Saner H. (2001). Approximations for trimmed Fisher procedures in
research synthesis. Statist. Methods Med. Res., 10: 267-276.
[45] Owen A.B. (2009). Karl pearson’s meta-analysis revisited. Annals of Statistics, 37:
3867-3892.
79
[46] Pirooznia M., Nagarajan V. and Deng Y. (2007). Gene venn - a web application for
comparing gene lists using venn diagram. Bioinformation, 1: 420-422.
[47] Rhodes D. et al. (2002). Meta-analysis of microarrays: interstudy validation of gene
expression profiles reveals pathway dysregulation in prostate cancer. Cancer research,
62: 4427-4433.
[48] Rosenthal R. (1994). Parametric measures of effect size. In H. Cooper & L. V.
Hedges (Eds.),The handbook of research synthesis (pp. 231-244), New York: Russell
Sage Foundation.
[49] Roy S.N. (1953). On a heuristic method of test construction and its use in multivariate
analysis. The Annals of Mathematical Statistics, 24(2): 220-238.
[50] Little R. and Rubin D. (2002). Statistical analysis with missing data, second edition.
John Wiley & Sons, Inc.: Hoboken, New Jersey.
[51] Segal E. et al. (2004). A module map showing conditional activity of expression
modules in cancer. Nature Genetics, 3: 1090-1098.
[52] Song C. and Tseng G.C. (2014). Order statistic for robust genomic meta-analysis.
Annals of Applied Statistics. Accepted.
[53] Stouffer S. et al. (1949). The American solider, volumn I: adjustement during army
life. Princeton University press.
[54] Sterne J. (editor) (2009). Meta-analysis in Stata: an updated collection from the Stata
Journal. Stata press.
[55] Tippett L.H.C. (1931). The methods in statistics. Williams and Norgate, LTD., 1st
edition.
[56] Tseng G.C. et al. (2012). Comprehensive literature review and statistical considera-
tions for microarray meta-analysis. Nucleic Acids Research, 40(9):3785-99.
80
[57] Wang X., Lin Y., Song C., Sibille E. and Tseng G.C. (2012). Detecting disease-
associated genes with confounding variable adjustment and the impact on genomic
meta-analysis: with application to major depressive disorder. BMC Bioinformatics,
13: 52.
[58] Wilkinson B. (1951). A statistical consideration in psychological research. Psycho-
logical Bulletin, 48: 156-157.
81
